Document:

EX-10.14

 Exhibit 10.14 
 EXECUTION VERSION 
 FORM
OF MT. SIGNAL 
 CONTRIBUTION AGREEMENT

 BY AND AMONG 

TERRAFORM POWER INC. 

TERRAFORM POWER, LLC 
 AND 
 SILVER RIDGE
POWER, LLC 
             , 2014

 Table of Contents 

 

							
	ARTICLE I DEFINITIONS	  	 	1	  
			
	 1.1
	 	 Certain Definitions
	  	 	1	  
			
	 1.2
	 	 Other Definitional and Interpretive Matters
	  	 	8	  
			
	 1.3
	 	 Joint Drafting
	  	 	9	  
		
	ARTICLE II CONTRIBUTION OF SHARES	  	 	9	  
			
	 2.1
	 	 Contribution and Consideration
	  	 	9	  
			
	 2.2
	 	 Consideration
	  	 	9	  
			
	 2.3
	 	 Closing
	  	 	10	  
			
	 2.4
	 	 Transfer Taxes
	  	 	10	  
		
	ARTICLE III REPRESENTATIONS AND WARRANTIES	  	 	10	  
			
	 3.1
	 	 Organization
	  	 	10	  
			
	 3.2
	 	 Authorization of Agreement
	  	 	10	  
			
	 3.3
	 	 Non-Contravention; Consents of Third Parties
	  	 	10	  
			
	 3.4
	 	 Legal Proceedings
	  	 	11	  
			
	 3.5
	 	 Financial Advisors
	  	 	11	  
		
	ARTICLE IV REPRESENTATIONS AND WARRANTIES BY SRP REGARDING THE COMPANY GROUP	  	 	12	  
			
	 4.1
	 	 Organization and Existence
	  	 	12	  
			
	 4.2
	 	 Capitalization and Subsidiaries
	  	 	12	  
			
	 4.3
	 	 Valid Issuance of Shares
	  	 	12	  
			
	 4.4
	 	 Title to Subsidiaries
	  	 	12	  
			
	 4.5
	 	 Investment Intent
	  	 	13	  
			
	 4.6
	 	 Investment Experience
	  	 	13	  
			
	 4.7
	 	 Accredited Investor
	  	 	13	  
			
	 4.8
	 	 No Other Representations or Warranties
	  	 	13	  
		
	ARTICLE V REPRESENTATIONS AND WARRANTIES BY THE YIELDCO ENTITIES	  	 	16	  
			
	 5.1
	 	 Organization and Existence
	  	 	16	  
			
	 5.2
	 	 Capitalization and Subsidiaries
	  	 	16	  
			
	 5.3
	 	 Governmental Consents
	  	 	16	  

  
 i 

							
			
	 5.4
	 	 Noncontravention
	  	 	17	  
			
	 5.5
	 	 YieldCo Shares
	  	 	17	  
			
	 5.6
	 	 Representations and Warranties in the Underwriting Agreement
	  	 	17	  
			
	 5.7
	 	 Organizational Documents
	  	 	18	  
			
	 5.8
	 	 Solvency
	  	 	18	  
			
	 5.9
	 	 Investment Intent
	  	 	18	  
			
	 5.10
	 	 No Material Misstatements or Omissions
	  	 	18	  
			
	 5.11
	 	 Investment Experience
	  	 	18	  
			
	 5.12
	 	 Accredited Investor
	  	 	19	  
			
	 5.13
	 	 Stock Exchange Listing
	  	 	19	  
			
	 5.14
	 	 Investment Company
	  	 	19	  
			
	 5.15
	 	 Acknowledgements
	  	 	19	  
		
	ARTICLE VI COVENANTS	  	 	20	  
			
	 6.1
	 	 Tax Characterization
	  	 	20	  
			
	 6.2
	 	 Purchase Price Allocation
	  	 	20	  
		
	 ARTICLE VII CLOSING
	  	 	20	  
			
	 7.1
	 	 Closing Deliverables
	  	 	20	  
		
	ARTICLE VIII SURVIVAL; INDEMNIFICATION	  	 	21	  
			
	 8.1
	 	 Survival
	  	 	21	  
			
	 8.2
	 	 Indemnification
	  	 	22	  
			
	 8.3
	 	 Indemnification Procedures
	  	 	23	  
			
	 8.4
	 	 Certain Limitations on Indemnification
	  	 	25	  
			
	 8.5
	 	 Calculation of Losses
	  	 	26	  
			
	 8.6
	 	 Tax Treatment of Indemnity Payments
	  	 	26	  
		
	ARTICLE IX MISCELLANEOUS	  	 	26	  
			
	 9.1
	 	 Expenses
	  	 	26	  
			
	 9.2
	 	 Governing Law
	  	 	26	  
			
	 9.3
	 	 Submission to Jurisdiction; Consent to Service of Process
	  	 	26	  
			
	 9.4
	 	 Entire Agreement; Amendments and Waivers
	  	 	27	  
			
	 9.5
	 	 Notices
	  	 	27	  

  
 ii 

							
			
	 9.6
	 	 Severability
	  	 	28	  
			
	 9.7
	 	 Specific Performance
	  	 	28	  
			
	 9.8
	 	 Binding Effect; No Third-Party Beneficiaries
	  	 	28	  
			
	 9.9
	 	 Assignment
	  	 	28	  
			
	 9.10
	 	 Counterparts
	  	 	29	  

  

			
	Schedules	  	
		
	Schedule 1	  	Company Disclosure Schedule

  
 iii

 FORM OF MT. SIGNAL
CONTRIBUTION AGREEMENT 
 This CONTRIBUTION AGREEMENT (this
“Agreement”) is entered into as of             , 2014 (the “Effective Date”) by and among Terraform Power Inc., a Delaware corporation
(“YieldCo”), Terraform Power, LLC, a Delaware limited liability company and a subsidiary of YieldCo (“YieldCo LLC”), and Silver Ridge Power, LLC, a Delaware limited liability company (“SRP”).

 R E C I T A L S 
 WHEREAS, SRP owns, directly or indirectly, one hundred percent (100%) of the equity interests (the “Shares”) in Imperial Valley Solar 1 Holdings II, LLC (the
“Company”); 
 WHEREAS, SRP desires to contribute to YieldCo LLC, and YieldCo LLC desires to accept from SRP,
on the terms and conditions set forth herein, the Shares. 
 NOW, THEREFORE, in consideration of the premises and the agreements
in this Agreement, and for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the Parties hereto agree hereby as follows: 

ARTICLE I 

DEFINITIONS 
 1.1 Certain Definitions. Capitalized terms used in this Agreement shall have the following meanings: 
 “Affiliate” of any Person means any other Person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such first
Person; provided, that, other than in connection with Section 4.15, Section 5.16, Section 6.1 and Article VIII, no fund managed by, advised by or otherwise affiliated with Riverstone Investment Group
LLC or any portfolio company in which any such fund owns an interest (other than any Group Company) or any investors in or owners, directors, officers, employees, representatives or agents of such fund or portfolio company, acting in their capacity
as such, shall be considered an Affiliate of SRP or any Group Company; and provided, further, that no YieldCo Group Company nor SunEdison or any Affiliate of SunEdison shall be considered an Affiliate of SRP or any Group Company.

 “Agreement” has the meaning set forth in the preamble. 

“Anti-Corruption Laws” means, with respect to any Person, any Laws relating to anti-bribery or anti-corruption
(governmental or commercial) which apply to such Person or any of its equityholders or Representatives, including the Foreign Corrupt Practices Act of 1977, 15 USC 78dd-1, et seq., as amended, and the rules and regulations thereunder; the U.K.
Bribery Act of 2010; all national and international Laws enacted to implement the Organization for Economic Cooperation and Development Convention on Combating Bribery of Foreign Officials in International Business Transactions; and any other
comparable Laws of all jurisdictions in which such Person or any of its equityholders conduct business. 

  
 1 

 “A&R IVSI LLC Agreement” means the Amended and Restated Limited
Liability Company Agreement of Imperial Valley Solar 1 Holdings, LLC, a Delaware limited liability company, dated October 9, 2013. 
 “A&R Mt. Signal Indemnity Agreement” has the meaning set forth in Section 7.1(b)(iii). 
 “Business Day” means any day of the year on which national banking institutions in New York are open to the public for conducting business and are not required or authorized to close.

 “Claim Notice” has the meaning set forth in Section 8.3(a). 

“Closing” has the meaning set forth in Section 2.3. 

“Closing Date” has the meaning set forth in Section 2.3. 

“Code” means the Internal Revenue Code of 1986, as amended (or any corresponding provision or provisions of succeeding
law). 
 “Commission” means the United States Securities and Exchange Commission. 

“Company” has the meaning set forth in the recitals. 

“Company Disclosure Schedule” means the schedule attached hereto as Schedule 1. 

“Company Financial Statements” means (a) the audited consolidated balance sheets, together with the related
consolidated statement of operations and comprehensive income/loss, of the Company as of and for the fiscal year ended December 31, 2013 and (b) the unaudited consolidated balance sheet, together with related consolidated statement of
operations and comprehensive income/loss, of the Company as of and for the three months ended March 31, 2013. 

“Company Group” means the Company and all of its Subsidiaries, if any. 

“Consideration” has the meaning set forth in Section 2.1. 

“Contribution Transaction” has the meaning set forth in Section 2.2. 

“De Minimis” has the meaning set forth in Section 8.4(a). 

“Disqualified Person” means (a) any federal, state or local government (including any political subdivision, agency
or instrumentality thereof), (b) any organization described in Section 501(c) of the Code and exempt from tax under Section 501(a) of the Code, (c) any entity referred to in Section 54(j)(4) of the Code, (d) any Person
described in Section 50(d)(1) of the Code, (e) any Person who is not a “United States Person” as defined in Section 7701(a)(30) of 

  
 2 

 
the Code (other than a foreign partnership or foreign passthrough entity), unless such Person is a foreign person or entity that is subject to U.S. federal income tax on more than fifty percent
(50%) of the gross income for the taxable year derived by such Person from the Mt. Signal Project Company and thus qualifies for the exception of section 168(h)(2)(B) of the Code, or (f) any partnership or other “pass-through
entity” (within the meaning of Section 1603(g)(4) of the American Recovery and Reinvestment Tax Act of 2009, as amended, including a single-member disregarded entity and a foreign partnership or foreign pass-through entity, but excluding a
“real estate investment trust” as defined in section 856(a) of the Code and a cooperative organization described in section 1381(a) of the Code, neither of which shall constitute a pass-through entity for purposes of this clause (f)) any
direct or indirect partner (or other holder of an equity or profits interest) of which is described in clauses (a) through (e) above unless such person owns such direct or indirect interest in the partnership or pass-through entity through
a “taxable C corporation”, as that term is used in the Section 1603 Program Guidance; provided, that if and to the extent the definition of “disqualified person” under Section 1603(g) of the American Recovery and
Reinvestment Tax Act of 2009, as amended, is amended after the date hereof, the definition of “Disqualified Person” hereunder shall be interpreted to conform to such amendment and any guidance issued by the U.S. Treasury Department with
respect thereto. 
 “Effective Date” has the meaning set forth in the preamble. 

“Enforceability Exceptions” has the meaning set forth in Section 3.2. 

“FERC” means the Federal Energy Regulatory Commission and any successor agency thereto. 

“FERC Approval” means the approval of FERC pursuant to Section 203 of the Federal Power Act of 1935, as amended by
the Energy Policy Act of 2005. 
 “Final Determination” means (a) a decision, judgment, decree or other
order by any court of competent jurisdiction, which decision, judgment, decree or other order has become final, (b) a closing agreement made under Section 7121 of the Code (or a comparable agreement under the laws of a state, local, or
foreign taxing jurisdiction) with the relevant Governmental Entity or other administrative settlement with or final administrative decision by the relevant Governmental Entity, (c) a final disposition of a claim for refund, or (d) any
agreement between the parties hereto where they agree will have the same effect as an item in (a), (b), or (c) for purposes of this Agreement. 
 “Fundamental Representations” has the meaning set forth in Section 8.1(a). 
 “GAAP” means means United States generally accepted accounting principles. 
 “Governmental Entity” means any supra-national, national, state, provincial or local governmental authority, court, government or self-regulatory organization, commission, tribunal or
organization or any regulatory, administrative or other agency, or any political or other subdivision, department or branch of any of the foregoing. 

  
 3 

 “Group Company” means any company within the Company Group. 

“HSR Approval” has the meaning given to such term in the Master Transaction Agreement. 

“IFRS” means means the International Financial Reporting Standards, as issued and updated from time to time by the
International Accounting Standards Board. 
 “Indebtedness” means, with respect to any Person, (a) any
obligations or indebtedness for money borrowed from others or in respect of loans or advances; (b) liabilities evidenced by any note, bond, debenture or other debt security or secured by a Lien on any of such Person’s assets;
(c) purchase money obligations; (d) capitalized lease obligations, conditional sales contracts and other similar title retention instruments; (e) obligations to pay deferred purchase price of assets, services or securities, including
trade payables which are past due; (f) reimbursement obligations for letters of credit or similar instruments that have been drawn; (g) liabilities under any interest rate protection agreement, interest rate future agreement, interest rate
option agreement, interest rate swap agreement or other similar agreement; (h) any obligations or indebtedness of the type described in subsections (a)-(g) above that is guaranteed, directly or indirectly, in any manner by such Person or
for which such Person may be liable, but excluding endorsements of checks in the ordinary course of business; (i) interest expense accrued but unpaid on or relating to any of such obligations or indebtedness; and (j) any prepayment
penalties, premiums, late charges, penalties and collection fees relating to any indebtedness described in subsections (a) through (i). 
 “Indemnification Claim” has the meaning set forth in Section 8.3(a). 
 “Indemnitees” has the meaning set forth in Section 8.2(c). 
 “Indemnitor” has the meaning set forth in Section 8.2(c). 
 “IPO” means the initial public offering by YieldCo of YieldCo Class A Shares. 
 “Law” means all foreign, federal, state and local laws, statutes, codes, ordinances, rules, regulations, resolutions and Orders. 

“Legal Proceeding” means any judicial, administrative or arbitral actions, suits or proceedings (public or private) by
or before a Governmental Entity or arbiter. 
 “Liabilities” means any and all direct or indirect liability,
Indebtedness, obligation, commitment, losses, damages, expense, claim, deficiency, guaranty or endorsement of any type, whether accrued, absolute, contingent, matured, or unmatured. 

“Lien” means any lien, encumbrance, pledge, mortgage, deed of trust, security interest, claim, lease, charge, option,
right of first refusal, easement, servitude, transfer restriction, encroachment, reservation, municipal bond or other restriction of any kind. 
 “Lock-Up Agreement” means a lock-up agreement (if any) entered into with YieldCo’s underwriter in connection with the initial public offering by YieldCo. 

  
 4 

 “Losses” means any and all claims, injuries, lawsuits, liabilities, losses,
damages, judgments, fines, penalties, costs and expenses, including the reasonable fees and disbursements of counsel (including fees of attorneys and paralegals, whether at the pre-trial, trial, or appellate level, or in arbitration) and all amounts
reasonably paid in investigation, defense, or settlement of any of the foregoing. 
 “Master Transaction
Agreement” means that certain Master Transaction Agreement by and among SunEdison, SRP and Riverstone dated as of June 16, 2014. 
 “Material Adverse Effect” means, with respect to any Person, a material adverse effect on (i) the business, assets, properties, results of operations, condition (financial or
otherwise) or performance of such Person and its Subsidiaries (taken as a whole) or (ii) the ability of such Person to consummate the Contribution Transaction. 
 “Mt. Signal Indemnity Agreement” has the meaning set forth in Section 7.1(b)(iii). 
 “Mt. Signal Property” means the property eligible for the Section 1603 Grants in connection with the development by the Mt. Signal Project Company of the photovoltaic power plant
located on certain real property in Imperial County, California. 
 “Order” means any order, injunction,
judgment, decree, determination, ruling, writ, assessment or other award of a Governmental Entity or arbiter. 

“Organizational Documents” means, with respect to any Person, the articles or certificate of incorporation or
organization and by-laws, the limited partnership agreement, the partnership agreement or the limited liability company agreement, operating agreement or the trust agreement, or such other organizational documents of such Person, including those
that are required to be registered or kept in the jurisdiction of incorporation, organization or formation of such Person and which establish the legal personality of such Person. 

“Organizational Transactions” has the meaning set forth for such term in the Registration Statement on Form S-1
(Registration No. 333-196345) initially submitted by Yieldco to the Commission on February 14, 2014 and publicly filed on May 29, 2014, as subsequently amended, including the contribution to YieldCo LLC of certain solar energy
projects developed by SunEdison and its Affiliates and the completion by YieldCo LLC of the acquisition of certain solar energy projects developed by third parties. 
 “Party” means each of YieldCo, YieldCo LLC and SRP individually, and “Parties” means all of them collectively. 

“Permits” means any approvals, authorizations, consents, licenses, permits or certificates of a Governmental Entity.

 “Permitted Liens” means, with respect to a Person, (a) imperfections of title, easements, encumbrances,
restrictions and other Liens that do not materially interfere with the ability of the such Person to conduct its businesses or to utilize its properties or assets for their intended 

  
 5 

 
purposes, (b) materialmen’s, mechanics’, carriers’, workmen’s, warehousemen’s, repairmen’s and other like Liens arising in the ordinary course of business, or
deposits to obtain the release of such Liens, to the extent relating to amounts not yet due and payable or being contested in good faith, (c) Liens for Taxes not yet due and payable or being contested in good faith, (d) only with respect
to the Company, Liens that secure debt obligations and (e) zoning, entitlement and other land use and environmental regulations promulgated by any Governmental Entity that do not materially interfere with the ability of such Person to conduct
its businesses or to utilize its properties or assets for their intended purposes. 
 “Person” means any
individual, corporation, partnership, firm, joint venture, association, joint-stock company, trust, unincorporated organization, Governmental Entity or other entity. 
 “Purchase Price Allocation Schedule” has the meaning set forth in Section 6.2. 
 “Recapture Period” has the meaning set forth in the A&R IVSI LLC Agreement. 
 “Representatives” means, as to any Person, the officers, directors, managers, employees, authorized agents, counsel, accountants, financial advisers and consultants of such Person.

 “Representing Party” has the meaning set forth in the preamble to Article III. 

“Riverstone” has the meaning set forth in the preamble. 

“SEC Disclosure” means any disclosure included in the SEC Documents, but excluding (i) any risk factor disclosure
contained in any such SEC Document under the heading “Risk Factors” or “Cautionary Note Regarding Forward-Looking Statements” or similar heading, (ii) any other statements that are predictive or primarily cautionary in
nature and (iii) any information set forth in any exhibit to any such SEC Document. 
 “SEC Documents” has
the meaning set forth in Section 5.10. 
 “Securities Act” means the Securities Act of 1933, as
amended, and the rules and regulations promulgated thereunder. 
 “Shares” has the meaning set forth in the
recitals. 
 “SRP” has the meaning set forth in the preamble. 

“SRP Indemnitees” has the meaning set forth in Section 8.2(a). 

“SRP Indemnitor” has the meaning set forth in Section 8.2(b). 

“Subsidiary” means, with respect to any Person, (i) a corporation a majority of whose capital stock with the
general voting power under ordinary circumstances to vote in the election of directors of such corporation (irrespective of whether or not, at the time, any other class or classes of securities shall have, or might have, voting power by reason of
the happening of any contingency) is, at the date of determination thereof, beneficially owned by such Person, by one 

  
 6 

 
or more Subsidiaries of such Person or by such Person and one or more Subsidiaries thereof or (ii) any other Person (other than a corporation), including a joint venture, a general or
limited partnership or a limited liability company, in which such Person, one or more Subsidiaries thereof or such Person and one or more Subsidiaries thereof, directly or indirectly, at the date of determination thereof, beneficially own at least a
majority of the ownership interests entitled to vote in the election of directors, managers or trustees thereof (or other Persons performing such functions) or act as the general partner or managing member of such other Person. 

“SunEdison” means SunEdison, Inc., a Delaware corporation. 

“Survival Period” has the meaning set forth in Section 8.1(d). 

“Tax” means any foreign or United States federal, state, or local income, profits, franchise, transfer, withholding, ad
valorem, personal property (tangible and intangible), employment, payroll, sales and use, value added (VAT), social security, disability, occupation, real property, severance, or excise tax and any other tax, charge, levy or other similar assessment
imposed by a Taxing Authority, including any interest, penalty or addition thereto. 
 “Tax Returns” means any
return, report or similar statement required to be filed with a Taxing Authority with respect to any Taxes (including any attached schedules), including any information return, claim for refund, amended return and declaration of estimated Tax.

 “Taxing Authority” means, with respect to any Tax, the Governmental Entity or political subdivision thereof
that imposes such Tax, and the agency (if any) charged with the collection of such Tax for such entity or subdivision. 

“Third Party” has the meaning set forth in Section 8.3(a). 

“Transaction Documents” means this Agreement and any other agreement, certificate, or other document executed by one or
more Parties and necessary for the implementation of this Agreement and the consummation of the Contribution Transaction. 

“UA Reps” has the meaning set forth in Section 5.6. 

“Underwriting Agreement” means that certain Equity Undewriting Agreement, dated as of
            , 2014, by and among the Yieldco Entities, SunEdison Holdings Corporation and the Underwriters. 
 “Underwriters” means Goldman, Sachs & Co., Barclays Capital Inc. and Citigroup Global Markets, Inc., as representatives of the several underwriters named in Schedule I to the
Underwriting Agreement. 
 “YieldCo” has the meaning set forth in the preamble. 

“Yield LLC” has the meaning set forth in the preamble. 

  
 7 

 “YieldCo Class B Shares” means shares of YieldCo Class B common stock, par
value $0.01. 
 “YieldCo Class B1 Shares” means shares of YieldCo Class B1 common stock, par value $0.01.

 “YieldCo Entities” means YieldCo and YieldCo LLC. 

“YieldCo Group” means, collectively, the YieldCo Entities and each of their respective Subsidiaries, and
“YieldCo Group Company” means, individually, any member of the YieldCo Group. 
 “YieldCo
Indemnitees” has the meaning set forth in Section 8.2(b). 
 “YieldCo Indemnitor” has the
meaning set forth in Section 8.2(a). 
 “YieldCo LLC” has the meaning set forth in the preamble.

 “YieldCo LLC B Units” means Class B Units of YieldCo LLC. 

“YieldCo LLC B1 Units” means Class B1 Units of YieldCo LLC. 

“YieldCo Material Contract” means a contract to which a YieldCo Group Company is a party or that is for the benefit of a
YieldCo Group Company, and that is material to the business, operations, financing or conduct of the YieldCo Group, taken as a whole. 
 “YieldCo Prospectus” has the meaning set forth in Section 5.10. 
 “YieldCo Registration Statement” has the meaning set forth in Section 5.10. 
 “YieldCo Shares” means, as applicable, the YieldCo LLC B Units, the YieldCo Class B Shares, the YieldCo LLC B1 Units and the YieldCo Class B1 Shares. 

“YieldCo Subsidiary” has the meaning set forth in Section 5.2(b). 

1.2 Other Definitional and Interpretive Matters. Unless otherwise expressly provided or the context otherwise requires, for
purposes of this Agreement, the following rules of interpretation shall apply: 
 (a) Calculation of Time Periods. When
calculating the period of time before which, within which or following which any act is to be done or step taken pursuant to this Agreement, the date that is the reference date in calculating such period shall be excluded. If the last day of such
period is a non-Business Day, the period in question shall end on the next succeeding Business Day. 
 (b) Dollars. Any
reference in this Agreement to “$” or dollars shall mean U.S. dollars. 

  
 8 

 (c) Exhibits/Schedules. The Exhibits and Schedules to this Agreement are an integral
part of this Agreement and are hereby incorporated herein and made a part hereof as if set forth herein. Any capitalized terms used in any Schedule or Exhibit but not otherwise defined therein shall be defined as set forth in this Agreement.

 (d) Gender and Number. Any reference in this Agreement to gender shall include all genders, and words imparting the
singular number only shall include the plural and vice versa. 
 (e) Headings. The provision of the Table of Contents,
the division of this Agreement into Articles, Sections and other subdivisions and the insertion of headings are for convenience of reference only and shall not affect or be utilized in construing or interpreting this Agreement. All references in
this Agreement to any “Article”, “Section” or other subdivision are to the corresponding Article, Section or other subdivision of this Agreement unless otherwise specified. 

(f) Herein. The words such as “herein,” “hereinafter,” “hereof,” “hereunder” and
“hereto” refer to this Agreement as a whole and not merely to a subdivision in which such words appear unless the context otherwise requires. 
 (g) Including. The word “including” or any variation thereof means “including, without limitation” and shall not be construed to limit any general statement that it follows to
the specific or similar items or matters immediately following it. 
 1.3 Joint Drafting. The Parties hereto have
participated jointly in the negotiation and drafting of this Agreement and, in the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as jointly drafted by the Parties hereto and no presumption or
burden of proof shall arise favoring or disfavoring any Party by virtue of the authorship of any provision of this Agreement. 

ARTICLE II 

CONTRIBUTION OF SHARES 
 2.1 Contribution and Consideration. Upon the terms and subject to the conditions of this Agreement, at the Closing, SRP will contribute, or shall cause its applicable Subsidiary to contribute as
set forth in Section 2.2 below, to YieldCo LLC, and YieldCo LLC will accept from SRP (or the applicable Subsidiary), all of the Shares, free and clear of all Liens other than Permitted Liens. 

2.2 Consideration. The consideration to be paid by YieldCo LLC to SRP (or its applicable Subsidiary) for the contribution of the
Shares shall be              (the “Consideration”). At the Closing, (a) YieldCo shall deliver to YieldCo LLC the YieldCo Class B Shares and the YieldCo Class B1 Shares
portion of the Consideration and (b) YieldCo LLC will deliver to SRP (or its applicable Subsidiary), and SRP (or its applicable Subsidiary) will accept from YieldCo LLC, the Consideration, free and clear of all Liens. The contribution of Shares
described in Section 2.1 and the payment of the Consideration described in this Section 2.2 are collectively referred to herein as the “Contribution Transaction.” 

  
 9 

 2.3 Closing. Each of the Parties acknowledges that the consummation of the
Contribution Transaction (the “Closing”) is taking place as of the execution of this Agreement, with legal effect as of 12:01 A.M. (Eastern time) on the Effective Date (the “Closing Date”). 

2.4 Transfer Taxes. YieldCo LLC shall be responsible for and pay any sales Taxes, transfer Taxes or similar Taxes that may be
payable with respect to the Contribution Transaction. 
 ARTICLE III 

REPRESENTATIONS AND WARRANTIES 
 Each Party (in such capacity, the “Representing Party”) hereby represents and warrants as of the Effective Date to the other Parties as follows: 

3.1 Organization. The Representing Party is duly organized, validly existing and in good standing under the Laws of its state of
formation. 
 3.2 Authorization of Agreement. The Representing Party has all requisite corporate or other entity power
and authority to execute and deliver each Transaction Document to which it is a party, to perform its obligations thereunder and to consummate the Contribution Transaction. The execution and delivery of the Transaction Documents and the consummation
of the Contribution Transaction have been duly authorized by all requisite corporate or other entity action on the part of the Representing Party. This Agreement has been duly and validly executed and delivered by the Representing Party and
(assuming the due authorization, execution and delivery by the other Parties) constitutes the legal, valid and binding obligations of the Representing Party, enforceable against it in accordance with its terms, subject to applicable bankruptcy,
insolvency, reorganization, moratorium and similar laws affecting creditors’ rights and remedies generally, and subject, as to enforceability, to general principles of equity, including principles of commercial reasonableness, good faith and
fair dealing (regardless of whether enforcement is sought in a proceeding at law or in equity) (the “Enforceability Exceptions”). Each of the other Transaction Documents to which the Representing Party is a party has been or shall
be duly and validly executed and delivered by the Representing Party and (assuming the due authorization, execution and delivery by the other parties thereto), when so executed and delivered, will constitute the legal, valid and binding obligations
of the Representing Party, enforceable against it in accordance with its terms, subject to the Enforceability Exceptions. 

3.3 Non-Contravention; Consents of Third Parties. 
 (a) None of the execution and delivery by the Representing Party of this Agreement or the other Transaction Documents, the consummation of the Contribution

  
 10 

 
Transaction, or compliance by the Representing Party with any of the provisions hereof or thereof, contravenes or will contravene, or result in any violation of or constitute a breach of or a
default (with or without notice or lapse of time, or both) under, or permit the acceleration of any obligation under, or give rise to a right of termination, modification or cancellation under (i) the Organizational Documents of the
Representing Party; (ii) any contract or Permit by which the Representing Party is bound or by which any of the properties or assets of the Representing Party are bound; (iii) any Order of any Governmental Entity applicable to the
Representing Party or by which any of the properties or assets of the Representing Party are bound; or (iv) any applicable Law; except, in the case of clauses (ii), (iii) and (iv), for such contraventions, violations, breaches, defaults,
accelerations, terminations, modifications or cancellations, as applicable, as could not, individually or in the aggregate, impair the ability of the Representing Party to perform its obligations under the Transaction Documents, or prevent or
materially impede, interfere with, hinder or delay the consummation of the Contribution Transaction. 
 (b) No consent, waiver,
approval, Order, Permit or authorization of, or declaration or filing with, or notification to, any Person or Governmental Entity is required on the part of the Representing Party in connection with the execution, delivery or performance of this
Agreement or the other Transaction Documents or the compliance by the Representing Party with any of the provisions hereof or thereof, or the consummation the Contribution Transaction, other than the HSR Approval and the FERC Approval and such other
consents, waivers, approvals, Permits, authorizations, declarations, filings or notifications that, if not obtained, made or given, could not, individually or in the aggregate, impair the ability of the Representing Party to perform its obligations
under the Transaction Documents, or prevent or materially impede, interfere with, hinder or delay the consummation of the Contribution Transaction. 
 3.4 Legal Proceedings. None of the Representing Party or its Affiliates is a party to any, and there are no pending or, to the knowledge of the Representing Party, threatened Legal Proceedings of
any nature that could have or could reasonably be expected to have a Material Adverse Effect on the Representing Party or that would prohibit the consummation of the Contribution Transaction. 

3.5 Financial Advisors. No Person has been engaged by or on behalf of the Representing Party to act, directly or indirectly, as a
broker, finder or financial advisor for the Representing Party and no Person is entitled to any fee or commission or like payment from the Representing Party or any other Person for so acting in connection with the Contribution Transaction.

  
 11 

 ARTICLE IV 
 REPRESENTATIONS AND WARRANTIES BY SRP REGARDING THE COMPANY GROUP 
 Except
as disclosed in, or qualified by any matter set forth in, the Company Disclosure Schedule (it being understood by the Parties that any information disclosed in one subsection of the Company Disclosure Schedule shall be deemed disclosed for purposes
of the other subsections of the Company Disclosure Schedule if the relevance of such information to such other subsections of the Company Disclosure Schedule is reasonably apparent on its face), SRP hereby represents and warrants as of the Effective
Date to YieldCo and YieldCo LLC as follows: 
 4.1 Organization and Existence. Each Group Company (a) is duly
organized and validly existing and in good standing under the laws of its jurisdiction of organization; (b) has the requisite corporate or other entity power and authority to own, lease and operate its assets and to carry on its business as
currently conducted and planned to be conducted; and (c) is duly qualified or licensed to transact business in each jurisdiction in which the properties owned, leased or operated by it or the nature of the business conducted by it makes such
qualification necessary, except, in the case of this clause (c), for those jurisdictions where the failure to be so qualified could not have, or could not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect on
the Company Group. 
 4.2 Capitalization and Subsidiaries. No Group Company owns any (a) direct or indirect equity
interest, participation or voting right in any other Person, other than in any other Group Company, or (b) options, warrants, convertible securities, exchangeable securities, subscription rights, conversion rights, exchange rights, stock
appreciation rights, phantom stock, profit participation or other similar rights in or issued by any other Person other than a Group Company, and no such interests, securities or rights are outstanding (other than pursuant to this Agreement) in
respect of any Group Company other than those held by other Group Companies. 
 4.3 Governmental Consents. No consent,
approval, order, license, authorization or waiver of, or registration or filing with, any Governmental Entity which has not been obtained or made by any Group Company is required to be obtained or made by any Group Company in connection with the
execution and delivery of this Agreement by SRP and the consummation by SRP of the transactions contemplated hereby other than HSR Approval and FERC Approval and such other consents, approvals, orders, licenses, authorizations, waivers,
registrations or filings that, if not obtained or made, could not have, or could not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect on the Company Group. 

4.4 Noncontravention. The execution, delivery and performance of this Agreement and the other Transaction Documents by SRP does
not, and the consummation by SRP of the Contribution Transaction will not, (a) contravene, violate or breach any of the terms, conditions or provisions of the Organizational Documents of any Group Company, (b) contravene, violate or breach
any provision of, or result in the termination or acceleration or default of, or entitle any party to accelerate any obligation or Indebtedness under, any Company Material Contract or result in the imposition or creation of any Lien (other than
Permitted Liens) on any assets material to the Company Group, or (c) contravene, or result in a violation or breach of any Law applicable to any Group Company or any of its assets material to the Company Group or require any consent or approval
of any third party under any applicable Law, except, in the case of clauses (b) and (c), for such contraventions, violations, breaches, terminations, accelerations or defaults which have not resulted in, or could not reasonably be expected to
result in, individually or in the aggregate, a Material Adverse Effect on the Company Group. 

  
 12 

 4.5 Valid Issuance of Shares. The Shares have been duly authorized by the Company
and, when delivered to YieldCo LLC and paid for by YieldCo LLC as provided herein, will be duly and validly issued, will be fully paid and nonassessable, and will be delivered to YieldCo LLC free and clear of all Liens and devoid of any preemptive
or similar rights. 
 4.6 Title to Subsidiaries. Each Group Company is the direct legal and beneficial owner of, and has
good and marketable title to, the equity interests reflected to be owned by such Person in Section 4.6 of the Company Disclosure Schedule, free and clear of all Liens other than those arising pursuant to the express terms (without any breach,
violation or default thereof) of this Agreement, the Organizational Documents of a Group Company, or applicable securities Laws or as disclosed in Section 4.6 of the Company Disclosure Schedule, no Group Company owns any direct or indirect
equity interest, participation or voting right in any other Person, other than in the Persons set forth in Section 4.6 of the Company Disclosure Schedule. No Group Company is a party to any written or oral agreement, and has not granted to any
Person (other than a Group Company) any option or any right or privilege capable of becoming an agreement or option for the purchase of, or subscription by, or the allotment or issue to any Person (other than a Group Company), any unissued
interests, units or other securities (including convertible securities, warrants or convertible obligations of any nature) of any Group Company and no shares, membership interests or other equity interests of any Group Company are subject to any
voting trust, shareholder agreement, pledge agreement, preemptive right, right of first refusal, right to purchase, voting agreement, or similar contract in favor of any Person other than a Group Company. 

4.7 Financial Statements; Absence of Changes; No Undisclosed Liabilities. 

(a) The Company Financial Statements have been prepared in accordance with GAAP (or as applicable, IFRS to the extent consistently
applied by the Company or SRP), or is accompanied by GAAP (or IFRS) reconciliations, and fairly present (subject, however, in the case of the any interim period financial statements, to normal year-end audit adjustments and accruals and to the
absence of notes and other textual disclosures required by GAAP or IFRS, as applicable) in all material respects the consolidated assets, financial position and consolidated results of operations of the Company Group as of the date thereof or for
the period set forth therein. 
 (b) Except for Liabilities disclosed in Section 4.7(b) of the Company Disclosure Schedule,
the Company Group has no Liabilities that are required to be reflected in the Company Financial Statements in accordance with GAAP (or IFRS), which (i) are not reflected or reserved against in the Company Financial Statements, (ii) were
incurred outside of the ordinary course of business and (iii) are in excess of $5,000,000 individually. 
 4.8
Litigation. There are no claims pending or, to the knowledge of SRP, threatened, against any Group Company, or the officers, directors or managers of any Group Company that (i) affect the Company Group or the assets of the Company Group
and have had, or could reasonably be expected to, cause, individually or in the aggregate, a Material 

  
 13 

 
Adverse Effect on the Company Group or (ii) seek a writ, judgment, order, injunction or decree restraining, enjoining or otherwise prohibiting or making illegal or subjecting to any
condition the use of the assets of the Company Group or the Contribution Transaction. 
 4.9 Intercompany Obligations;
Affiliate Transactions. 
 (a) Except for ordinary course trade payables, and except as set forth in Section 4.9 of the
Company Disclosure Schedule, there is no outstanding Indebtedness between any Group Company, on the one hand, and any Affiliate of SRP (other than a Group Company), on the other hand. 

(b) Other than as a direct or indirect holder of an equity interest in a Group Company, and except as set forth in Section 4.9 of
the Company Disclosure Schedule, neither SRP nor any Affiliate thereof (other than a Group Company) (i) is a party to any contract or transaction with a Group Company or (ii) has any interest in any real property or assets of any Group
Company. 
 4.10 Anti-Corruption Matters. Except as would not be material to any Group Company in the past five years,
neither any Group Company, nor, to the knowledge of SRP, any of their respective owners, members, Subsidiaries, Affiliates, partnerships, or Representatives (nor, to the knowledge of SRP, any director, officer, employee, member or other third party
acting directly or indirectly for or on behalf of any such Persons), has taken any action in violation of any Anti-Corruption Laws. Neither any Group Company, nor or any of their respective owners, members, Subsidiaries, Affiliates, partnerships, or
Representatives (nor, to the knowledge of SRP, any director, officer, employee, member or other third party acting directly or indirectly for or on behalf of any such Persons) has been convicted of violating any Anti-Corruption Laws or been
subjected to any investigation or inquiry by a Governmental Entity relating to potential corruption, fraud or violation of any Anti-Corruption Laws. Neither any Group Company, nor any of their respective owners, members, Subsidiaries, Affiliates,
partnerships, or Representatives (nor, to the knowledge of SRP, any director, officer, employee, member or other third party acting directly or indirectly for or on behalf of any such Persons) has received, conducted an internal investigation and/or
been investigated for any claim or allegation, whether from internal sources or outside sources, relating to any possible violation of any Anti-Corruption Laws. 
 4.11 Solvency. 
 (a) No petition or notice has been presented, no order has
been presented, no order has been made and no resolution has been passed for the bankruptcy, liquidation, winding-up or dissolution of any Group Company. 
 (b) No receiver, trustee, custodian or similar fiduciary has been appointed over the whole or any part of the assets or the income of any Group Company. 

(c) No Group Company has any plan or intention of filing, making or obtaining any such petition, notice, order or resolution or of
seeking the appointment of a receiver, trustee, custodian or similar fiduciary. 

  
 14 

 4.12 Investment Intent. The YieldCo Shares to be received by SRP as Consideration
will be acquired for investment for SRP’s own account and not with the view to, or for resale in connection with, any distribution thereof (except a distribution to its own members), and SRP has no present intention of selling, granting any
participation in, or otherwise distributing the same (except for any distribution to its own members). SRP further represents that it does not have any contract, undertaking, agreement or arrangement with any person or entity to sell, transfer or
grant participation to such person or entity or to any third person or entity with respect to any of YieldCo Shares (except for any distribution to its own members). SRP has not been formed for the specific purpose of acquiring the YieldCo Shares.

 4.13 Investment Experience. SRP has substantial experience in evaluating transactions similar to the Contribution
Transaction and acknowledges that it can protect its own interests. SRP has such knowledge and experience in financial and business matters so that SRP is capable of evaluating the merits and risks of the Contribution Transaction. 

4.14 Accredited Investor. SRP is an “accredited investor” within the meaning of Regulation D, Rule
501(a), promulgated by the Commission under the Securities Act.  
 4.15 No Other Representations or Warranties. Except for the
representations and warranties contained in this Article IV (as modified by the Company Disclosure Schedule), neither SRP nor any of its Affiliates or Representatives makes any other express or implied representation or warranty with respect to the
Company Group or the businesses, operations or assets of the Company Group or any other assets, rights or obligations to be transferred hereunder or pursuant to this Agreement, and SRP disclaims any other representations or warranties, whether made
by SRP or any of its Affiliates or its Representatives. The Parties agree that neither SRP nor any other Person on behalf of SRP (i) makes any representation or warranty or (ii) will have any or be subject to any liability or obligation
with respect to any projections or probable or future revenues, expenses, profitability or financial results of the Company Group, any material made available to Yieldco, Yieldco LLC or any of their Affiliates or Representatives at any time in
certain “data rooms”, management presentations, “break-out” discussions, responses to questions submitted by or on behalf of Yieldco, Yieldco LLC or its Affiliates, whether orally or in writing, or in any other form in
expectation or furtherance of the transactions contemplated by this Agreement. 

  
 15 

 ARTICLE V 
 REPRESENTATIONS AND WARRANTIES BY THE YIELDCO ENTITIES 
 Except as
disclosed in, or qualified by any matter set forth in any SEC Disclosure contained in the SEC Documents, YieldCo and YieldCo LLC, jointly and severally, hereby represent and warrant as of the Effective Date (assuming, for the purposes of this
Article V and Article VIII, that the IPO and all of the Organizational Transactions have been consummated) to SRP as follows: 
 5.1 Organization and Existence. Each YieldCo Entity (a) is duly organized and validly existing and in good standing under the laws of its jurisdiction of organization; (b) has the
requisite corporate or other entity power and authority to own, lease and operate its assets and to carry on its business as currently conducted and planned to be conducted; and (c) is duly qualified or licensed to transact business in each
jurisdiction in which the properties owned, leased or operated by it or the nature of the business conducted by it makes such qualification necessary, except, in the case of this clause (c), for those jurisdictions where the failure to be so
qualified could not have, or could not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect on the YieldCo Group. 
 5.2 Capitalization and Subsidiaries. 
 (a) The SEC Disclosure sets forth
the number of shares, or partnership, membership interests or other equity interests, of the authorized capital stock of each of the YieldCo Entities and the number and class of shares, partnership, membership or other equity interests, thereof duly
issued and outstanding. 
 (b) Each Subsidiary of YieldCo and YieldCo LLC (each, other than with respect to YieldCo, YieldCo
LLC, a “YieldCo Subsidiary”) and its jurisdiction of formation or organization is set forth on Exhibit 21.1 of the YieldCo Registration Statement, other than certain YieldCo Subsidiaries that are being contributed to YieldCo on or
substantially concurrently with the Effective Date pursuant to the Organizational Transactions and are not reflected on Exhibit 21.1. No YieldCo Entity owns any interests (whether equity, voting, participating or otherwise) in any Person other than
the YieldCo Subsidiaries. Each YieldCo Subsidiary is (i) duly organized and validly existing and in good standing under the laws of its jurisdiction of organization, (ii) has the requisite corporate or other entity authority to own, lease
and operate its assets and to carry on its business as currently conducted and planned to be conducted and (iii) is duly qualified or authorized to do business as a foreign corporation or entity and is in good standing under the laws of each
jurisdiction in which the conduct of its business or the ownership of its properties requires such qualification or authorization, except, in the case of this clause (iii), for those jurisdictions where the failure to be so qualified could not have,
or could not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect on the YieldCo Group. 

5.3 Governmental Consents. No consent, approval, order, license, authorization or waiver of, or registration or filing with, any
Governmental Entity which has not been obtained or made by a YieldCo Entity is required to be obtained or made by any YieldCo Entity in connection with the execution and delivery of this Agreement and the consummation of the transactions
contemplated hereby other than such consents, approvals, orders, licenses, authorizations, waivers, registrations or filings that, if not obtained or made, could not have, or could not reasonably be expected to have, individually or in the
aggregate, a Material Adverse Effect on the YieldCo Group. 

  
 16 

 5.4 Noncontravention. The execution, delivery and performance of this Agreement and
the other Transaction Documents by YieldCo and YieldCo LLC do not, and the consummation by YieldCo and YieldCo LLC of the Contribution Transaction will not, (a) contravene, violate or breach any of the terms, conditions or provisions of the
Organizational Documents of any YieldCo Entity, (b) contravene, violate or breach any provision of, or result in the termination or acceleration or default of, or entitle any party to accelerate any obligation or Indebtedness under, any YieldCo
Material Contract or result in the imposition or creation of any Lien (other than Permitted Liens) on any assets material to the YieldCo Group, or (c) contravene, or result in a violation or breach of any Law applicable to any YieldCo Entity or
any material assets of the YieldCo Group or require any consent or approval of any third party under any applicable Law, except, in the case of clauses (b) and (c), for such contraventions, violations, breaches, terminations, accelerations or
defaults which have not resulted in, or could not reasonably be expected to result in, individually or in the aggregate, a Material Adverse Effect on the YieldCo Group. 
 5.5 YieldCo Shares. The YieldCo Shares delivered pursuant to Section 2.2 have been duly authorized by each of the YieldCo Entities, as applicable, and, when delivered to SRP and paid for by
SRP as provided herein, will be duly and validly issued, will be fully paid and nonassessable, and will be delivered to SRP free and clear of all Liens. Except as set forth in the Organizational Documents of the applicable YieldCo Entity, no YieldCo
Entity is a party to any written or oral agreement, and has not granted to any Person any option, or any right or privilege capable of becoming an agreement or option, for the purchase of, or subscription by, or the allotment or issue to issue to
any Person of, any unissued interests, units or other securities (including convertible securities, warrants or convertible obligations of any nature) of itself and no shares, membership interests or other equity interests of the respective YieldCo
Entity are subject to any voting trust, shareholder agreement, pledge agreement, preemptive right, right of first refusal, right to purchase, voting agreement, or similar contract in favor of any Person. Other than the fact that the YieldCo Class B
Shares have a right to ten votes per share and the YieldCo Class B1 Shares have one vote per share, and except as disclosed on Amendment No. 1 to the Form S-1 of YieldCo, as submitted to the Commission on June 16, 2014, there are no
material differences between the rights, obligations or liabilities of holders of YieldCo Class B Shares and holders of YieldCo Class B1 Shares under the Organizational Documents of YieldCo or otherwise. Except as disclosed on Amendment No. 1
to the Form S-1 of YieldCo, as submitted to the Commission on June 16, 2014, there are no material differences between the rights, obligations or liabilities of holders of YieldCo LLC B Units and YieldCo LLC B1 Units under the Organizational
Documents of Yieldco LLC or otherwise. 
 5.6 Representations and Warranties in the Underwriting Agreement. As of the
date that the Underwriting Agreement is entered into by YieldCo and the Underwriters and the Closing Date, YieldCo hereby makes the same representations and warranties to SRP as the Company makes to the Underwriters in Sections
         of the Underwriting Agreement (the “UA Reps”). For purposes of this Section 5.6, each reference in such UA Reps to “this Agreement” shall be deemed to be a reference to
this Agreement, other than where appropriate cross references are made to other provisions of the Underwriting Agreement, and the defined terms used in the UA Reps shall have the same meaning as ascribed to them in the Underwriting Agreement.

  
 17 

 5.7 Organizational Documents. A true, complete and correct copy of the
Organizational Documents of each of the YieldCo Entities has been made available to SRP. 
 5.8 Solvency. 

(a) No petition or notice has been presented, no order has been presented, no order has been made and no resolution has been passed for
the bankruptcy, liquidation, winding-up or dissolution of any of the YieldCo Group Companies. 
 (b) No receiver, trustee,
custodian or similar fiduciary has been appointed over the whole or any part of the assets or the income of any of the YieldCo Group Companies. 
 (c) No YieldCo Group Company has any plan or intention of filing, making or obtaining any such petition, notice, order or resolution or of seeking the appointment of a receiver, trustee, custodian or
similar fiduciary. 
 5.9 Investment Intent. YieldCo LLC hereby confirms that the Shares to be received by YieldCo LLC
will be acquired for investment for its own account and not with the view to, or for resale in connection with, any distribution thereof, and YieldCo LLC does not have any present intention of selling, granting any participation in, or otherwise
distributing the same. YieldCo LLC further represents that it does not have any contract, undertaking, agreement or arrangement with any person or entity to sell, transfer or grant participation to such person or entity or to any third person or
entity with respect to any of the Shares. YieldCo LLC has not been formed for the specific purpose of acquiring the Shares. 

5.10 No Material Misstatements or Omissions. The Registration Statement of YieldCo on Form S-1 (Reg. No. 333-196345) (the
“YieldCo Registration Statement”), as of the date of it was declared effective and as of the date hereof, did not and does not contain an untrue statement of a material fact or omit to state a material fact required to be stated
therein or necessary to make the statements therein not misleading and the prospectus of YieldCo filed with the Commission on             , 2014 (the “YieldCo
Prospectus” and, together with the YieldCo Registration Statement, the “SEC Documents”), as of its date and as of the date hereof, did not and does not contain any untrue statement of a material fact or omit or omits to
state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. 
 5.11 Investment Experience. Each of the YieldCo Entities has substantial experience in evaluating transactions similar to the Contribution Transaction and acknowledges that it can protect its own
interests. Each of the YieldCo Entities has such knowledge and experience in financial and business matters so that such Person is capable of evaluating the merits and risks of the Contribution Transaction. 

  
 18 

 5.12 Accredited Investor. Each of the YieldCo Entities is an “accredited
investor” within the meaning of Regulation D, Rule 501(a), promulgated by the Securities and Exchange Commission under the Securities Act. 
 5.13 Stock Exchange Listing. Neither of the YieldCo Entities has received any notice of delisting. This Agreement will not contravene NASDAQ rules and regulations. 

5.14 Investment Company. None of the YieldCo Entities is now, or after the closing of this Agreement will be, an “investment
company” or a company “controlled by” an “investment company” within the meaning of the Investment Company Act of 1940, as amended. 
 5.15 Disqualified Person. No YieldCo Group Company is a Disqualified Person. 
 5.16 Acknowledgements. 
 (a) IT IS UNDERSTOOD AND AGREED THAT, UNLESS
EXPRESSLY STATED HEREIN, SRP IS NOT MAKING AND HAS NOT AT ANY TIME MADE ANY WARRANTIES OR REPRESENTATIONS OF ANY KIND OR CHARACTER, EXPRESS OR IMPLIED, WITH RESPECT TO THE COMPANY GROUP OR THE BUSINESSES, OPERATIONS OR ASSETS OF THE COMPANY GROUP,
INCLUDING BUT NOT LIMITED TO, ANY WARRANTIES OR REPRESENTATIONS AS TO MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF ANY ASSETS OF THE COMPANY GROUP. 
 (b) YIELDCO AND YIELDCO LLC ACKNOWLEDGE AND AGREE THAT, UNLESS EXPRESSLY STATED HEREIN, UPON CLOSING SRP SHALL CONTRIBUTE ALL OF ITS RIGHT, TITLE AND INTEREST IN AND TO THE COMPANY TO YIELDCO LLC AND
YIELDCO LLC SHALL ACCEPT THE COMPANY GROUP AND THE ASSETS OF THE COMPANY GROUP “AS IS, WHERE IS, WITH ALL FAULTS.” YIELDCO AND YIELDCO LLC HAVE NOT RELIED AND WILL NOT RELY ON, AND SRP IS NOT LIABLE FOR OR BOUND BY, ANY EXPRESS OR
IMPLIED WARRANTIES, GUARANTEES, STATEMENTS, REPRESENTATIONS OR INFORMATION PERTAINING TO THE COMPANY GROUP OR ANY OF THE BUSINESSES, OPERATIONS OR ASSETS OF THE COMPANY GROUP OR RELATING THERETO MADE OR FURNISHED BY SRP, ITS AFFILIATES OR ITS
REPRESENTATIVES, TO WHOMEVER MADE OR GIVEN, DIRECTLY OR INDIRECTLY, ORALLY OR IN WRITING, IN EACH CASE EXCEPT AS EXPRESSLY STATED HEREIN. YIELDCO AND YIELDCO LLC ALSO ACKNOWLEDGE THAT THE CONSIDERATION REFLECTS AND TAKES INTO ACCOUNT THAT, EXCEPT AS
EXPRESSLY STATED HEREIN, THE COMPANY GROUP AND THE ASSETS OF THE COMPANY GROUP ARE BEING SOLD “AS IS, WHERE IS, WITH ALL FAULTS.” 
 (c) YIELDCO AND YIELDCO LLC ACKNOWLEDGE TO SRP THAT YIELDCO AND YIELDCO LLC HAVE HAD THE OPPORTUNITY TO CONDUCT, PRIOR TO THE EFFECTIVE DATE, SUCH INSPECTIONS AND INVESTIGATIONS OF THE COMPANY, ANY
GROUP COMPANY AND THEIR RESPECTIVE BUSINESS, OPERATIONS AND ASSETS AS YIELDCO AND YIELDCO LLC DEEMED NECESSARY OR DESIRABLE TO SATISFY THEMSELVES AS TO THE COMPANY, ANY GROUP COMPANY AND THEIR RESPECTIVE BUSINESS, OPERATIONS AND ASSETS AND ITS
ACQUISITION THEREOF. YIELDCO AND YIELDCO LLC FURTHER WARRANT AND REPRESENT TO SRP THAT YIELDCO AND YIELDCO LLC WILL RELY SOLELY ON THEIR OWN REVIEW, INSPECTIONS AND INVESTIGATIONS IN THIS TRANSACTION AND NOT UPON THE

  
 19 

 
INFORMATION PROVIDED BY OR ON BEHALF OF SRP, OR ITS AGENTS, EMPLOYEES OR REPRESENTATIVES WITH RESPECT THERETO. YIELDCO AND YIELDCO LLC HEREBY ASSUME THE RISK THAT ADVERSE MATTERS INCLUDING, BUT
NOT LIMITED TO, LATENT OR PATENT DEFECTS, ADVERSE PHYSICAL OR OTHER ADVERSE MATTERS, MAY NOT HAVE BEEN REVEALED BY YIELDCO’S OR YIELDCO LLC’S REVIEW, INSPECTIONS AND INVESTIGATIONS. 

ARTICLE VI 

COVENANTS 
 6.1 Tax Characterization For U.S. federal income tax purposes (and for purposes of any applicable U.S. state or local tax purposes that follow the U.S. federal income tax treatment), the Parties
agree to treat the contribution of the Shares by SRP to YieldCo LLC in exchange for YieldCo Shares as qualifying for nonrecognition of gain or loss pursuant to Section 721 of the Code (including, to the extent applicable, by reason of
assumption of a qualified liability under Treas. Reg. § 1.707-5 or a reimbursement of preformation capital expenditures under Treas. Reg. § 707-4(d)). The Parties will prepare and file all Tax Returns consistent with the
foregoing and will not take any inconsistent position on any Tax Return, or during the course of any audit, litigation, or other proceeding with respect to Taxes, except as otherwise required by applicable Law following a Final Determination.

 6.2 Purchase Price Allocation. Section 6.2 of the Company Disclosure Schedule sets forth the allocation of the
Consideration and any other amounts properly treated as consideration for U.S. federal income tax purposes (to the extent known at such time) among the assets of the Company Group (the “Purchase Price Allocation Schedule”). The
Parties agree to revise the Purchase Price Allocation Schedule to take into account any subsequent adjustments to the Consideration. The Parties will not, and will cause their Affiliates to not, file any Tax Return or otherwise take any position
with respect to Taxes (including during the course of any audit or other proceeding) which is inconsistent with the Purchase Price Allocation Schedule, as finally determined, except to the extent otherwise required by applicable Law following a
Final Determination. 
 6.3 Transfer Restriction. During the period ending on
                    , YieldCo and YieldCo LLC shall not permit the Mt. Signal Property to be owned by a Disqualified Person. 

ARTICLE VII 
 CLOSING 
 7.1 Closing Deliverables. 

(a) Upon the terms and subject to the conditions of this Agreement, at the Closing, SRP has delivered, or caused to have been delivered,
to YieldCo LLC or YieldCo each of the following: 
 (i) the Lock-Up Agreement; 

(ii) the Shares by delivering a written instrument of assignment and evidence of the transfer thereof, free and clear of
any Liens other than Permitted Liens. 

  
 20 

 (b) Upon the terms and subject to the conditions of this Agreement, at the Closing, YieldCo
LLC or YieldCo has delivered, or caused to have been delivered, to SRP, or its designee, each of the following: 

(i) the Consideration by [delivering a written instrument of assignment and evidence of the transfer thereof, free and
clear of any Liens or interests of any Person] [and/or] [wire transfer of immediately available funds, to an account designated in writing (or via email) by SRP at least one Business Day prior to the Closing Date; and 

(ii) [a certificate of Yield Co LLC’s or YieldCo’s transfer agent certifying as to the book entry of the
Consideration]. 
 (iii) YieldCo LLC shall deliver (A) an executed indemnity agreement in the form of that
certain Indemnity Agreement dated as of November 9, 2012, by and among AES U.S. Solar, LLC, AES Solar Power, LLC, Imperial Valley Solar 1, LLC and R/C US Solar Investment Partnership, L.P. (the “Mt. Signal Indemnity Agreement”)
pursuant to which YieldCo LLC will make representations and covenants with respect to itself in substance similar to those set forth in Sections 3 and 4(a) and (b) of the Mt. Signal Indemnity Agreement and which will remain in effect until the
second anniversary of the end of the Recapture Period) (the “A&R Mt. Signal Indemnity Agreement”) and (B) an executed side letter in favor of Imperial Valley Solar 1, LLC which shall contain provisions, in form and
substance satisfactory to Imperial Valley Solar 1, LLC, which restrict until the second anniversary of the end of the Recapture Period any direct or indirect transfers of ownership by such purchaser or transferee to any Disqualified Person or that
would otherwise result in loss or liability resulting from any portion of any grant in lieu of tax credits paid to Imperial Valley Solar 1, LLC with respect to the Mount Signal Property pursuant to Section 1603 of the American Recovery and
Reinvestment Tax Act of 2009, as amended, being “recaptured,” disallowed, reduced or unavailable. 
 ARTICLE VIII

 SURVIVAL; INDEMNIFICATION 
 8.1 Survival. 
 (a) The representations and warranties contained in
Sections 3.2 (Authorization of Agreement), 3.5 (Financial Advisors), 4.5 (Valid Issuance of Shares), 4.6 (Title to Subsidiaries), 5.1 (Organization and Existence), 5.2 (Capitalization and Subsidiaries),
5.4 (Noncontravention), 5.5 (YieldCo Shares) and 5.16 Acknowledgements (the “Fundamental Representations”) shall survive the Closing without time limit. All other representations and warranties contained in this
Agreement or in any certificate delivered pursuant to this Agreement shall survive the Closing until the date that is eighteen (18) months following the Effective Date. 

  
 21 

 (b) All covenants, obligations and agreements of the Parties under this Agreement which
expressly contemplate performance after the Closing Date shall survive the Closing Date for the period of time contemplated or specified therein. Any covenants, obligations and agreements under this Agreement that are performed in full pursuant to
their terms prior to the Closing Date shall not survive the Closing for any purpose. 
 (c) Each of the Parties acknowledges
that, from and after the Closing Date, it will not have any claims or causes of action or any right to indemnification pursuant to this Article VIII or otherwise for a breach of any representation, warranty, covenant or agreement which
does not survive the Closing Date. 
 (d) The applicable survival period set forth above for each such representation, warranty,
covenant, obligation or agreement, is referred to herein as a “Survival Period.” 
 8.2
Indemnification. 
 (a) Subject to the limitations set forth in this Agreement, from and after the Closing Date, YieldCo
and YieldCo LLC (in such capacity, the “YieldCo Indemnitor”) agrees to indemnify SRP and each of its respective Affiliates and Representatives (collectively, “SRP Indemnitees”) and to hold each of them harmless from
and against any and all Losses suffered, paid or incurred by such SRP Indemnitee (i) resulting from or relating to any breach of any of the representations and warranties made by the YieldCo Indemnitor in this Agreement, including pursuant to
Article III and Article V, (ii) caused by any breach by the YieldCo Indemnitor of any of its covenants, obligations or agreements contained herein, or (iii) for any material misstatement or omission contained in the SEC
Documents, taken as a whole, as of the Closing Date; provided that the indemnification obligations of each of the YieldCo Entities shall be joint and several among the YieldCo Entities. 

(b) Subject to the limitations set forth in this Agreement, from and after the Closing Date, SRP (in such capacity, the “SRP
Indemnitor”) agrees to indemnify YieldCo and YieldCo LLC and each of their respective Affiliates and Representatives (collectively, “YieldCo Indemnitees”) and to hold each of them harmless from and against any and all
Losses suffered, paid or incurred by such YieldCo Indemnitee (i) resulting from or relating to any breach of any of the representations and warranties made by the SRP Indemnitor in this Agreement, including pursuant to Article III and
Article IV, or (ii) caused by any breach by the SRP Indemnitor of any of its covenants, obligations or agreements contained herein. 
 (c) The YieldCo Indemnitors and the SRP Indemnitors are referred to in this Article VIII generically as “Indemnitors” and the YieldCo Indemnitees and the SRP Indemnitees are
referred to in this Article VIII generically as “Indemnitees”. 
 (d) Each of the Parties acknowledges
and agrees that no Party shall have any liability under any provision of this Agreement for any Loss to the extent that such Loss relates to action taken by such Party or any other Person after the Closing Date. Each of the Parties shall take and
shall cause its Affiliates to take all reasonable steps to mitigate any Loss upon 

  
 22 

 
becoming aware of any event which would reasonably be expected to, or does, give rise thereto, including incurring costs only to the minimum extent necessary to remedy the breach which gives rise
to the Loss. 
 (e) (i) SRP shall be fully and unconditionally released from, and YieldCo LLC shall assume, all of the
obligations of Imperial Valley Solar 1, LLC under the Mt. Signal Indemnity Agreement arising after the Closing, and (ii) YieldCo and YieldCo LLC shall jointly and severally indemnify SRP and its Affiliates for any Losses incurred by SRP in
connection with YieldCo LLC’s obligations under the A&R Mt. Signal Indemnity Agreement, based on events, conditions or circumstances arising after the Closing and (iii) SRP shall indemnify YieldCo and YieldCo LLC for one-half of any
Losses incurred by them in connection with YieldCo and YieldCo LLC’s obligations under the A&R Mt. Signal Indemnity Agreement based on events, conditions or circumstances arising prior to the Closing. 

8.3 Indemnification Procedures. 
 (a) In the event that any Legal Proceedings shall be instituted or that any claim or demand shall be asserted by any Person in respect of which payment may be sought under Section 8.2, the
Indemnitee shall assert its claim for indemnification (an “Indemnification Claim”) by giving written notice thereof (a “Claim Notice”) to the applicable Indemnitor (i) if the Indemnification Claim is, or
relates to, a claim brought by a Person not a Party or an Affiliate of a Party (a “Third Party”), within 10 Business Days following receipt by Indemnitee of notice of such claim, or (ii) if the Indemnification Claim is not, or
does not relate to, a claim brought by a Third Party, within 30 days after the discovery by the Indemnitee of the facts, events or circumstances giving rise to such Indemnification Claim; provided, that no delay on the part of an Indemnitee
in giving a Claim Notice shall relieve the Indemnitor of any indemnification obligation hereunder unless the Indemnitor demonstrates that the defense of such Indemnification Claim is materially and adversely prejudiced by such delay. Each Claim
Notice shall describe in reasonable detail the facts and circumstances with respect to the subject matter of such claim. 
 (b)
Upon receipt by an Indemnitor of a Claim Notice in respect of a claim of a Third Party, the Indemnitor shall be entitled to (i) assume and have sole control over the defense of such claim at its sole cost and expense and with its own counsel if
it gives notice of its intention to do so to the Indemnitee within thirty (30) days of the receipt of the Claim Notice from the Indemnitee; and (ii) negotiate a settlement or compromise of such claim; provided, that (x) such
settlement or compromise shall include a full and unconditional waiver and release by the Third Party of all Indemnitees (without any cost or liability of any nature whatsoever to such Indemnitees) and (y) any such settlement or compromise
shall be permitted hereunder only with the written consent of the Indemnitee, which shall not be unreasonably withheld, conditioned or delayed. Notwithstanding anything herein to the contrary, the Indemnitor shall not be entitled to assume control
of the defense and settlement of a claim of a Third Party and shall pay the fees and expenses of counsel retained by the Indemnitee if such claim of the Third Party relates to or arises in connection with any criminal proceeding, action, indictment,
allegation or claim or a primary objective of such claim is to seek equitable or injunctive relief against the Indemnitee. If, within 30 days of receipt from an Indemnitee of any Claim Notice with respect to a Third

  
 23 

 
Party claim, the Indemnitor (i) advises such Indemnitee in writing that the Indemnitor shall not elect to defend, settle or compromise such claim or (ii) fails to make such an election
in writing, such Indemnitee may, at its option, defend, settle or otherwise compromise or pay such claim; provided, that any such settlement or compromise shall be permitted hereunder only with the written consent of the Indemnitor, which
consent shall not be unreasonably withheld, conditioned or delayed. Unless and until the Indemnitor makes an election in accordance with this Section 8.3 to defend, settle or compromise such claim, all of the Indemnitee’s reasonable
costs and expenses arising out of the defense, settlement or compromise of any such claim shall be considered Losses subject to indemnification hereunder and shall be borne by the Indemnitor and payable monthly or as legal bills are received by the
Indemnitee and tendered to the Indemnitor. Each Indemnitee shall make available to the Indemnitor all information reasonably available to such Indemnitee relating to such claim, except as may be prohibited by applicable Law. In addition, the Parties
shall render to each other such assistance as may reasonably be requested in order to ensure the proper and adequate defense, negotiation or settlement of any such Indemnification Claim. The Party in charge of the defense shall keep the other
Parties fully apprised at all times as to the status of the defense or any settlement negotiations with respect thereto. If the Indemnitor elects to defend any such claim, then the Indemnitee shall be entitled to participate in such defense with
counsel reasonably acceptable to the Indemnitor, at such Indemnitee’s sole cost and expense; provided, that such Indemnitee shall be entitled to participate in any such defense with separate counsel at the reasonable expense of the
Indemnitor if (i) so requested by the Indemnitor, or (ii) in the reasonable opinion of counsel to the Indemnitee, a conflict or potential conflict of interests exists between the Indemnitee and the Indemnitor; and provided,
further, that the Indemnitor shall not be required to pay for more than one such counsel for all Indemnitees in connection with any Indemnification Claim. Notwithstanding the foregoing, if a settlement offer solely for money damages is made
by the applicable Third Party, and the Indemnitor notifies the Indemnitee in writing of the Indemnitor’s willingness to accept the settlement offer and, subject to the applicable limitations of Sections 8.4 and 8.5, pay the amount
called for by such offer, and the Indemnitee declines to accept such offer, the Indemnitee may continue to contest such Indemnification Claim, free of any participation by the Indemnitor, and the amount of any ultimate liability with respect to such
Indemnification Claim that the Indemnitor has an obligation to pay hereunder shall be limited to the lesser of (A) the amount of the settlement offer that the Indemnitee declined to accept plus the Losses of the Indemnitee relating to such
Indemnification Claim through the date of its rejection of the settlement offer or (B) the aggregate Losses of the Indemnitee with respect to such Indemnification Claim. If the Indemnitee makes any payment on any Indemnification Claim, the
Indemnitor shall be subrogated, to the extent of such payment, to all rights and remedies of the Indemnitee to any insurance benefits or other claims of the Indemnitee with respect to such Indemnification Claim. 

(c) After any final decision, judgment or award shall have been rendered by a Governmental Entity and the expiration of the time in which
to appeal therefrom, or a settlement shall have been consummated, or the Indemnitee and the Indemnitor shall have arrived at a mutually binding agreement with respect to an Indemnification Claim hereunder, the Indemnitee shall forward to the
Indemnitor notice of any sums due and owing by the Indemnitor pursuant to this Agreement with respect to such matter. 

  
 24 

 8.4 Certain Limitations on Indemnification. 

(a) Notwithstanding the foregoing or anything to the contrary set forth herein, no Party shall have any indemnification obligations under
Section 8.2(a)(i) or Section 8.2(b)(i), (i) for any individual item where the Loss relating thereto is less than $500,000 (the “De Minimis”) and (ii) in respect of each individual item where the
Loss relating thereto is equal to or greater than the De Minimis, unless the aggregate amount of all such Losses exceeds $1,500,000, in which case all Losses shall be indemnified from the first dollar. In no event shall the aggregate indemnification
to be paid by any Party pursuant to Section 8.2(a)(i) or Section 8.2(b)(i), as applicable, exceed $15,000,000. Notwithstanding the foregoing, the limitations set forth in this Section 8.4(a) shall not apply to any
breaches of Fundamental Representations. 
 (b) In no event shall the aggregate indemnification to be paid by any Party pursuant
to Article VIII exceed an amount in value equal to value of the Consideration as of the Closing. 
 (c) No representation
or warranty contained herein shall be deemed untrue or incorrect, and a Party shall not be deemed to have breached a representation or warranty, as a consequence of the existence of any fact, circumstance or event of which the other Party is aware
as of the Closing Date. 
 (d) NOTWITHSTANDING ANYTHING IN THIS AGREEMENT TO THE CONTRARY, NO PARTY NOR ANY OF ITS AFFILIATES
SHALL BE LIABLE TO THE OTHER PARTY OR ITS AFFILIATES PURSUANT TO THIS ARTICLE VIII FOR SPECIAL, PUNITIVE, EXEMPLARY, CONSEQUENTIAL, INCIDENTAL OR INDIRECT DAMAGES, INCLUDING LOSS OF FUTURE REVENUE, INCOME OR PROFITS, LOSS OF BUSINESS
REPUTATION OR OPPORTUNITY RELATING TO THE BREACH OR ALLEGED BREACH OF THIS AGREEMENT, OR DIMINUTION OF VALUE OR ANY DAMAGES BASED ON ANY TYPE OF MULTIPLE, WHETHER BASED ON CONTRACT, TORT, STRICT LIABILITY, OTHER LAW OR OTHERWISE AND WHETHER OR NOT
ARISING FROM THE OTHER PARTY’S OR ANY OF ITS AFFILIATES’ SOLE, JOINT OR CONCURRENT NEGLIGENCE, STRICT LIABILITY OR OTHER FAULT, EXCEPT TO THE EXTENT ONE OF THE PARTIES HERETO IS HELD LIABLE FOR SUCH CONSEQUENTIAL DAMAGES TO A THIRD PARTY
AND SUCH PARTY IS ENTITLED TO BE INDEMNIFIED BY ANY OF THE OTHER PARTIES HERETO PURSUANT TO THIS ARTICLE VIII (PROVIDED THAT SUCH LIMITATION WITH RESPECT TO LOST PROFITS SHALL NOT LIMIT SRP’S RIGHT TO RECOVER CONTRACT DAMAGES IN
CONNECTION WITH YIELDCO LLC’S OR YIELDCO’S FAILURE TO CLOSE IN VIOLATION OF THIS AGREEMENT). 
 (e) From and after the
Closing Date, the indemnities provided in this Article VIII shall be the sole and exclusive remedy of any Party against any other Party or its Affiliates at Law or in equity relating to the Transaction Documents, any other document or
certificate delivered in connection herewith or therewith, or the assets and liabilities of SRP or any applicable Law or otherwise; provided, that nothing in this Agreement shall prevent any Party from seeking an injunction or injunctions to
prevent breaches of this Agreement by the other Parties and to enforce specifically the terms and provisions hereof that expressly survive the Closing Date. 

  
 25 

 8.5 Calculation of Losses. The amount of any Losses for which indemnification is
provided under this Article VIII shall be net of any amounts actually recovered or recoverable by the Indemnitee under insurance policies or otherwise with respect to such Losses (net of any expenses incurred in connection with such recovery).

 8.6 Tax Treatment of Indemnity Payments. The Parties agree to treat any indemnity payment made pursuant to this
Article VIII as an adjustment to the Consideration for U.S. federal, state, local and non-U.S. Tax purposes, except to the extent required by applicable Law following a Final Determination. 

ARTICLE IX 

MISCELLANEOUS 
 9.1 Expenses. Except as otherwise provided in this Agreement, all costs and expenses incurred in connection with this Agreement and the transactions contemplated hereby shall be paid by the Party
incurring such costs and expenses, including any fees, expenses or other payments incurred or owed by a Party to any brokers, financial or legal advisors or comparable other Persons retained or employed by such Party in connection with the
Contribution Transaction. 
 9.2 Governing Law. This Agreement shall be governed and construed in accordance with the
Laws of the State of New York, without giving regard to any conflict of laws principles thereof that would result in the application of the Laws of another jurisdiction. 
 9.3 Submission to Jurisdiction; Consent to Service of Process. 
 (a) The
Parties hereby irrevocably submit to the exclusive jurisdiction of the state and federal courts located in the Borough of Manhattan, New York City, over any dispute arising out of or relating to this Agreement or the Contribution Transaction and
each party hereby irrevocably agrees that all claims in respect of such dispute or any suit, action or proceeding related thereto may be heard and determined in such courts. The Parties hereby irrevocably waive, to the fullest extent permitted by
applicable Law, any objection which they may now or hereafter have to the laying of venue of any such dispute brought in such court or any defense of inconvenient forum for the maintenance of such dispute. Each of the Parties agrees that a judgment
in any such dispute may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by Law. 

(b) Each of the Parties hereto hereby consents to process being served by any Party to this Agreement in any suit, action or proceeding
by delivery of a copy thereof in accordance with the provisions of Section 9.5. 

  
 26 

 9.4 Entire Agreement; Amendments and Waivers. The Transaction Documents (including
the Schedules hereto) represent the entire understanding and agreement between the Parties with respect to the subject matter hereof. This Agreement and the other Transaction Documents can be amended, supplemented or changed, and any provision
hereof can be waived, only by written instrument making specific reference to this Agreement signed by the Party against whom enforcement of any such amendment, supplement, modification or waiver is sought. No action taken pursuant to this
Agreement, including any investigation by or on behalf of any Party, shall be deemed to constitute a waiver by the Party taking such action of compliance with any representation, warranty, covenant or agreement contained herein. The waiver by any
Party hereto of a breach of any provision of this Agreement shall not operate or be construed as a further or continuing waiver of such breach or as a waiver of any other or subsequent breach. No failure on the part of any Party to exercise, and no
delay in exercising, any right, power or remedy hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of such right, power or remedy by such Party preclude any other or further exercise thereof or the exercise of any
other right, power or remedy. 
 9.5 Notices. All notices, requests and other communications hereunder shall be in
writing and shall be sent, delivered or mailed, addressed: 
 if to YieldCo or YieldCo LLC, to: 

TerraForm Power, Inc. 
 12500 Baltimore Avenue 
 Beltsville, Maryland 20705 

Attn: General Counsel 
 Facsimile: (443) 909-7106 
 with a copy to: 

Kirkland & Ellis LLP 
 300 North LaSalle 
 Chicago, Illinois 60654 

Attn: Dennis M. Myers, P.C. 
 Facsimile: (312) 862-2200 
 if to SRP, to: 

Silver Ridge Power, LLC 
 4301 N. Fairfax Drive, Suite 360 
 Arlington, VA 22203 

Attention: Stephen Westwell 
 Telecopy: (571) 302-3501 
 All notices and other communications given or made
pursuant to this Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt or (a) personal 

  
 27 

 
delivery to the Party to be notified; (b) upon receipt of a confirmatory telephone call to the number specified in this Section 9.5 (or in accordance with the latest unrevoked
written direction from the receiving Party), if sent by electronic mail; (c) five days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (d) one Business Day after deposit with a
nationally recognized overnight courier, freight prepaid, specifying next business day delivery, with written verification of receipt; provided, that notices received on a day that is not a Business Day or after 6:30 p.m. on a Business Day
will be deemed to be effective on the next Business Day. 
 9.6 Severability. If any term or other provision of this
Agreement is invalid, illegal, or incapable of being enforced by any law or public policy, all other terms or provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance of the
Contribution Transaction is not affected in any manner materially adverse to any Party. Upon such determination that any term or other provision is invalid, illegal, or incapable of being enforced, the Parties shall negotiate in good faith to modify
this Agreement so as to effect the original intent of the Parties as closely as possible in an acceptable manner in order that the Contribution Transaction is consummated as originally contemplated to the greatest extent possible. Except as
otherwise expressly provided for in this Agreement, nothing contained in any representation or warranty, or the fact that any representation or warranty may or may not be more specific than any other representation or warranty, shall in any way
limit or restrict the scope, applicability or meaning of any other representation or warranty contained in this Agreement. 

9.7 Specific Performance. Each Party acknowledges and agrees that any breach of this Agreement would give rise to irreparable
harm for which monetary damages would not be an adequate remedy. Each Party accordingly agrees that, in addition to any other remedies available under applicable Law or this Agreement, each Party shall be entitled to enforce the terms of this
Agreement by decree of specific performance without the necessity of proving the inadequacy of monetary damages as a remedy and to obtain injunctive relief against any breach or threatened breach of this Agreement. 

9.8 Binding Effect; No Third-Party Beneficiaries. This Agreement shall be binding upon and inure to the benefit of the Parties
and their respective successors and permitted assigns. Nothing in this Agreement shall create or be deemed to create any third party beneficiary rights in any Person or entity not a Party to this Agreement. 

9.9 Assignment. No assignment of this Agreement or of any rights or obligations hereunder may be made by any Party, directly or
indirectly (by operation of Law or otherwise), without the prior written consent of the other Parties and any attempted assignment without the required consents shall be null, void and of no effect; provided, that each Party may assign its
rights, interests and obligations hereunder to any of its direct or indirect Subsidiaries, and in the case of SRP to any member of SRP (or an Affiliate of such member) to whom SRP (or such member) distributes or otherwise transfers Consideration
other than in a transaction registered under the Securities Act; and provided, further, that no assignment of any obligations hereunder shall relieve the Parties hereto of any such obligations. Upon any such permitted assignment, the
references in this Agreement to a given Party shall also apply to any such assignee unless the context otherwise requires. 

  
 28 

 9.10 Counterparts. This Agreement may be executed in one or more counterparts,
including facsimile or PDF counterparts, each of which shall be deemed to be an original copy of this Agreement and all of which, when taken together, shall be deemed to constitute one and the same agreement. 

[signature page follows] 

  
 29 

 IN WITNESS WHEREOF, the Parties hereto have caused this Contribution Agreement to be
executed by their duly authorized representatives as of the date first written above. 
  

			
	TERRAFORM POWER, LLC
		
	By:	 	  

	Name:	 	
	Title:	 	
	
	TERRAFORM POWER, INC.
		
	By:	 	  

	Name:	 	
	Title:	 	
	
	SILVER RIDGE POWER, LLC
		
	By:	 	  

	Name:	 	
	Title:Exhibit 10.1

 

CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED BASED UPON A REQUEST FOR CONFIDENTIAL TREATMENT AND THE NON-PUBLIC INFORMATION HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

PATENT ASSIGNMENT AND LICENSE AGREEMENT

 

This Patent Assignment and License Agreement (hereinafter the “Agreement”), effective as of April 23, 2014 (the “Effective Date”), is entered by and between:

 

TROVAGENE, INC., a California company with offices located at 11055 Flintkote Avenue, San Diego California, 92121 (hereinafter referred to as “Trovagene”);

 

and

 

GENSIGNIA IP LTD., a UK company with offices located at 18 South Street, Mayfair, London, W1K 1DG, United Kingdom (hereinafter referred to as “GenSignia”);

 

RECITALS

 

A.         WHEREAS Trovagene owns or has exclusive rights in or to certain patents and patent applications related to certain diagnostic tests;

 

B.         WHEREAS GenSignia desires to obtain an assignment of Trovagene’s rights in such patents and patent applications; and

 

C.         WHEREAS, subject to the terms and conditions set forth in this Agreement, Trovagene is willing to assign its rights in such patents and patent applications to GenSignia subject to receiving a perpetual, exclusive, irrevocable license in the Field (as defined below).

 

NOW, THEREFORE, in consideration of the foregoing premises and mutual agreements, covenants and conditions herein contained all the Parties hereto hereby agree as follows:

 

Article 1                                          Definitions

 

For purposes of this Agreement, the following terms shall have the meanings set forth below:

 

1.1                              “Affiliate” shall mean with respect to any corporation, partnership or other business entity a Person or any other Person controlling, controlled by or under common control with such Person.  For purposes of this definition, “control” (including with correlative meaning, the terms “controlled by” and “under common control with”) shall mean, directly or indirectly, the ownership of fifty percent (50%) or more of the voting securities or other voting interests of such Person, or the ability or power to direct or cause the direction of management policies of such Person or otherwise direct the affairs of such Person.

 

1.2                              “Bundled Product” shall mean a Product for which Net Sales is calculated that is sold or otherwise transferred or delivered with one or more other products or services in circumstances where the price of such Product is either not shown separately on the invoice or is shown as nil (free of charge).

 

1.3                              “Bundled Product Adjustment” means the following:

 

1

 

CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED BASED UPON A REQUEST FOR CONFIDENTIAL TREATMENT AND THE NON-PUBLIC INFORMATION HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

(a)                                  In the event of a Bundled Product, then Net Sales for such Bundled Product shall be calculated, on a country-by-country basis, by multiplying actual Net Sales of such Bundled Product by the fraction A/(A+B), where A is the average gross invoiced sales amount of the Product if sold separately in finished form, and B is the average gross invoiced sales amount of all other products or services in finished form in such country.

 

(b)                                  If, on a country-by-country basis, the Products are sold separately in finished form in such country but the other products or services in the Bundled Product are not sold separately in finished form in such country, Net Sales shall be calculated by multiplying actual Net Sales of such Bundled Product by the fraction C/(C+D), where C is the average gross invoiced sales amount of the Products in finished form in such country, and D is the difference between the average gross invoice sales amount of the Bundled Product and the average sales price of the Products in finished form in such country.

 

(c)                                   If, on a country-by-country basis, the other products or services in the Bundled Product are sold separately in finished form in such country but the Products are not sold separately in finished form in such country, Net Sales shall be calculated by multiplying actual Net Sales of such Bundled Product by the fraction 1 minus C/(C+D), where C is the average gross invoiced sales amount of the other products or services in finished form in such country, and D is the difference between the average gross invoiced sales amount of the Bundled Product and the average gross invoiced sales amount of the other products or services in finished form in such country.

 

(d)                                  If, on a country-by-country basis, neither the Products nor the other products or services of the Bundled Product are sold separately in finished form in such country, Net Sales of the Bundled Product shall be determined by the Parties in good faith based on the relative fair market value for the Products and products or services, as applicable.

 

1.4                              “Confidential Information” means any and all information, data, results, inventions, trade secrets, techniques, material, or compositions of matter of any type or kind, including without limitation all know-how and all other scientific, pre-clinical, clinical, regulatory, manufacturing, marketing, personnel, financial, legal and commercial information or data, whether communicated in writing, orally or by any other method, that a Party treats or identifies as confidential and, in each case, is disclosed by one Party to the other Party with respect to such disclosing Party’s rights or obligations under this Agreement.

 

1.5                              “Distributors” shall mean any Third Party appointed by GenSignia or any of its Affiliates to distribute, market and sell Products of GenSignia or any of its Affiliates that:  (i) is not required to make royalty or other similar payment to GenSignia or any of its Affiliates with respect to any Transferred Patent whose claims cover the Product; and (ii) has no right to market such Product under its own trademark or trade name.

 

1.6                              “End User” shall mean the ultimate user or practicer of a Product.

 

2

 

CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED BASED UPON A REQUEST FOR CONFIDENTIAL TREATMENT AND THE NON-PUBLIC INFORMATION HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

1.7                              “Field” shall mean use, practice or other exploitation in urine for any and all indications, including for the performance of diagnostic tests in urine.

 

1.8                              “Licensee” shall mean any individual or entity to whom GenSignia or any of its Affiliates grants a license to research, develop, make, have made, use, sell, offer to sell, have sold,  import or otherwise practice or exploit Products covered by Transferred Patent Rights in the Territory.

 

1.9                              “License Income” shall mean all up-front fees, license signing fees, milestone payments, success fees, royalties and other consideration received by GenSignia or its Affiliates from Licensees on account of the use or sale of Products or grant of a license under the Transferred Patents; provided, however that License Income will not include: (a) amounts paid by such licensee as reimbursement for research and development costs incurred under such license with respect to Products in the event GenSignia collaborates on research and/or development with such a licensee; (b) bona fide loans with market terms; (c) fair market value reimbursement for clinical trial costs and expenses; (d) equity investment in GenSignia at the market value for such equity; (e) amounts paid at fair market value for supplies of Products or other tangible materials, or that are otherwise paid in reimbursement of costs or expenditures, whether incurred before or after the date of the relevant license agreement; (f) upfront fees and milestone payments payable solely for products other than the Products, and (g) withholding taxes or other amounts actually witheld from the amounts received, paid to a governmental authority and not reimbursed by Licensee or any Third Party.  License Income shall also not include amounts received in connection with a merger, consolidation or sale of all or substantially all of the business or assets of GenSignia to which this Agreement relates.

 

1.10                       “Net Sales” shall mean, with respect to each Product, the total amount invoiced by GenSignia and its Affiliates and Distributors for sales of Products to Third Parties (other than Distributors in the Territory, except as set forth below), less the following deductions with respect to such sale, to the extent applicable to the Products, and to the extent actually allowed and/or taken:  (i) trade, cash and quantity credits, discounts, credits, and refunds, (ii) allowances or credits for returns or rejected Product; (iii) prepaid freight and insurance; (iv) sales taxes and other governmental charges (including value added and similar taxes, but solely to the extent not otherwise creditable or reimbursed and excluding any income tax) actually paid by GenSignia or its Affiliates in connection with the sale; and (v) customary rebates (including, for this purpose, discounts provided by means of chargebacks or rebates) actually granted to managed health care organizations, federal, state, or local governments (or their agencies) (including without limitation Medicaid rebates), all to the extent in accordance with GAAP as consistently applied across all Products.

 

For the avoidance of any doubt, (i) sales between GenSignia and its Affiliates, or (ii) from GenSignia or any of its Affiliates to any of its or their Distributors or Licensees shall be excluded from the computation of Net Sales, except in connection with sales where such Affiliates, Distributors or Licensees are End Users.

 

3

 

CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED BASED UPON A REQUEST FOR CONFIDENTIAL TREATMENT AND THE NON-PUBLIC INFORMATION HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

Such amounts shall be determined from books and records maintained in accordance with the law under which GenSignia is organized.

 

1.11                       “Party” or “Parties” shall mean either Trovagene or GenSignia or both, as applicable.

 

1.12                       “Pending Patent Claim” means a claim in a pending patent application within the Transferred Patents that has not been abandoned, expired or held finally rejected by a decision of a court or governmental authority of competent jurisdiction over such claim, and which rejection is not appealable or has not been appealed within the time allowed for appeal.

 

1.13                       “Person” shall mean a natural person, a corporation, a partnership, a trust, a joint venture, a limited liability company, any governmental authority or any other entity or organization.

 

1.14                       “Products” shall mean (i) any process which is covered, in whole or in part, by any Pending Patent Claim or any Valid Claim of any Transferred Patent; and (ii) any any product, the manufacture, use or sale of which is covered, in whole or in part, by any Pending Patent Claim or any Valid Claim of any Transferred Patent.

 

1.15                       “Reserved Indication” shall mean the performance of diagnostic tests for lung cancer in the Field.

 

1.16                       “Royalty Term” means, with respect to a Product, for each country in the Territory, the period of time commencing on the first commercial sale of such Product in any country and ending upon the expiration of the last Valid Patent Claim.

 

1.17                       “Territory” means all of the countries in the world, and their territories and possessions, where there is a Valid Patent Claim or Pending Patent Claim in effect.

 

1.18                       “Third Party” or “Third Parties” shall mean any individual, entity or entities other than GenSignia, Trovagene, and their respective Affiliates.

 

1.19                       “Transferred Patents” shall mean:

(i)                        all patents and patent applications listed in Exhibit A attached hereto, and any patents issuing on such patent applications;

(ii)                     any divisional, continuations, continuations-in-part, refiling, and extensions of any of the foregoing patents and patent applications;

(iii)                  all substitutions, reissues, renewals, re-examinations, patents of addition, and inventors’ certificates thereof, patent term extensions, supplementary protection certificates and exclusivity extensions of the foregoing patents; and

(iv)                 any foreign counterparts with respect to any of the foregoing.

 

1.20                       “Valid Patent Claim” means a claim of an issued and unexpired Transferred Patent or a Pending Patent Claim, which, in either case, has not been revoked or held unenforceable or invalid, or held finally rejected, by a decision of a court or other governmental agency of competent jurisdiction over such claim, and which is not appealable or has not been appealed within the time allowed for appeal, and which has not been disclaimed, denied or admitted to be invalid or unenforceable through reissue,

 

4

 

CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED BASED UPON A REQUEST FOR CONFIDENTIAL TREATMENT AND THE NON-PUBLIC INFORMATION HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

re-examination or disclaimer, otherwise, and which has not been abandoned or expired.

 

Article 2                                          Assignment and Grant of License

 

2.1                         Assignment. Trovagene, concurrent with the execution of this Agreement, shall assign all right, title and interest in the Transferred Patents to GenSignia by executing the patent assignment document attached hereto as Exhibit B.

 

2.2                         License to Trovagene.  Upon the terms and subject to the conditions of this Agreement, subject to execution of the assignment in Section 2.1 above, GenSignia hereby grants to Trovagene an exclusive (even as to GenSignia), royalty-free, fully paid up, perpetual, irrevocable license under the Transferred Patents to research, develop, make, have made, use, sell, offer to sell, have sold, import and export, and otherwise practice and exploit Products in the Field in the Territory. Such license is freely transferable and sublicensable, in whole or in part, and including through multiple tiers.

 

2.3                         No Implied License. No right or license under any know-how, or other intellectual property other than the Transferred Patents is granted to GenSignia or shall be granted by implication or estoppel.

 

2.4                         Right of First Refusal.

 

(a)         Trovagene hereby grants to GenSignia an exclusive right of first refusal to negotiate a license under the Transferred Patents in the Reserved Indication, on the terms and subject to the conditions set forth in this Section 2.4.  Such right would be triggered by either:

 

i.     Trovagene’s written notification to GenSignia that Trovagene or its Affiliates intends to grant a Third Party a license or similar right to commercialize Products in the Reserved Indication in the Territory; or

 

ii.   GenSignia providing written notice to Trovagene of GenSignia’s interest in pursuing a license to the Transferred Patents in the Reserved Indication.

 

(b)         Upon receipt of such written notice, GenSignia shall have forty-five (45) days to negotiate a license under the Transferred Patents in the Reserved Indication with Trovagene on commercially reasonable terms. Unless otherwise agreed by the Parties in writing prior to the expiration of such forty-five (45) day period, Trovagene shall thereafter be free to enter into any agreement or other arrangement with any Third Party for a license or similar right to commercialize a Product in the Reserved Indication with no further obligation to GenSignia.

 

(c)          The foregoing right of first refusal shall not be triggered by, and nothing herein shall restrict Trovagene from developing Products on its own or in collaboration with any Third Parties or from commercializing Products in the Reserved

 

5

 

CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED BASED UPON A REQUEST FOR CONFIDENTIAL TREATMENT AND THE NON-PUBLIC INFORMATION HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

Indication itself, through its Affiliates and Distributors (without the grant of a commercialization license), or through a Third Party.

 

Article 3                                          Payments

 

3.1                               In consideration of all the rights granted to GenSignia herein, GenSignia shall pay the following amounts to Trovagene in accordance with written instructions provided by Trovagene to GenSignia, and, all such amounts shall be non-refundable:

 

(a)         Up-Front Payment: a single one-time payment of $* USD upon execution of this Agreement.

 

(b)         Milestone Payments: (i) a single one-time payment of $* USD upon the achievement of $* Net Sales in a calendar year, (ii) a single one-time payment of $* USD upon the achievement of $* Net Sales in a calendar year; and (iii) a single one-time payment of $* USD upon the achievement of $* Net Sales in a calendar year, each payable within thirty (30) days following achievement of such Net Sales milestone;

 

(c)          Royalties: Commencing upon first commercial sale of a Product in the Territory and continuing thereafter throughout the Royalty Term, GenSignia shall pay to Trovagene a royalty equal to * per cent (*%) of Net Sales of such Product in the Territory.  Royalty payments shall be made within thirty (30) days after the end of each calendar quarter for which royalties are due, and shall be payable on a country-by-country, product-by-product basis.  Upon expiration of the Royalty Term for a Product in a country, GenSignia may thereafter continue to sell such Product in such country on a royalty-free basis.  Notwithstanding the foregoing, in the event that during the Royalty Term, the only remaining Valid Claims with respect to a Product in a particular country are Pending Patent Claims that have been pending for more than seven (7) years, the obligation to pay royalties with respect to Net Sales occuring after such date shall be waived until the date such Pending Patent Claims issue, from which point forward all royalties for sales shall recommence and be due and payable and paid within thirty (30) days after the date GenSignia is first notified of the issuance of such Pending Patent Claims; and

 

(d)         Licensing: in the event that GenSignia derives any License Income during the Royalty Term, GenSignia shall pay * percent (*%) of all such License Income to Trovagene.  Such licensing payments shall be made within thirty (30) days after the end of each calendar quarter in which such payments are due.

 

* Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portion.

 

6

 

CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED BASED UPON A REQUEST FOR CONFIDENTIAL TREATMENT AND THE NON-PUBLIC INFORMATION HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

Article 4                                          Publicity, Use of Names.

 

4.1                               General. Either Party shall be free to disclose, without the other Party’s prior written consent, the existence of this Agreement, the identity of the other Party and those terms of the Agreement which the parties have mutually agreed in writing may be publicly disclosed.

 

4.2                               No Implied License. Except as set forth in Section 4.1, or as expressly permitted by this Agreement, neither Party shall use the name, trademark, trade name or logo of the other Party or its employees, in any publicity, news release or disclosure relating to this Agreement or its subject matter, without the prior express written permission of the other Party.

 

Article 5                                          Representations and Warranties

 

5.1                               Mutual Representations and Warranties.  Each Party hereby represents and warrants to the other Party as follows:

 

(a)         Corporate Existence and Power.  It is a corporation duly organized, validly existing and in good standing under the laws of the state in which it is incorporated, and has full corporate power and authority and the legal right to own and operate its property and assets and to carry on its business as it is now being conducted and as contemplated in this Agreement, including, without limitation, the right to grant the licenses granted hereunder.

 

(b)         Authority and Binding Agreement.  As of the Effective Date, (i) it has the corporate power and authority and the legal right to enter into this Agreement and perform its obligations hereunder; (ii) it has taken all necessary corporate action on its part required to authorize the execution and delivery of the Agreement and the performance of its obligations hereunder; and (iii) the Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid and binding obligation of such Party and is enforceable against it in accordance with its terms.

 

(c)          No Conflict.  It has not entered, and will not enter, into any agreement with any Third Party which is in conflict with the rights granted to the other Party under this Agreement, and has not taken and will not take any action that would in any way prevent it from granting the rights granted to the other Party under this Agreement, or that would otherwise materially conflict with or adversely affect the rights granted to the other Party under this Agreement.

 

5.2                               Trovagene Representations and Warranties.  Trovagene represents and warrants to GenSignia that as of the Effective Date, it owns the entire right, title and interest under the Transferred Patents necessary to execute the assignment in this Agreement.

 

7

 

CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED BASED UPON A REQUEST FOR CONFIDENTIAL TREATMENT AND THE NON-PUBLIC INFORMATION HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

5.3                               No Other Representations or Warranties.  The express representations and warranties stated in this Article 5 are in place of all other representations and warranties, express, implied, or statutory, including without limitation, warranties of merchantability, fitness for a particular purpose, non-infringement or non-misappropriation of Third Party intellectual property rights, title, custom or trade.

 

Article 6                                          Confidentiality

 

6.1                               Nondisclosure Obligation.  All Confidential Information shall be maintained in confidence by the receiving Party and shall not be disclosed to any Third Party or used for any purpose except to exercise its rights and perform its obligations under this Agreement without the prior written consent of the disclosing Party, except to the extent that the receiving Party can demonstrate by competent written evidence that such Confidential Information: (i) is known by the receiving Party at the time of its receipt and not through a prior disclosure by the disclosing Party, as documented by the receiving Party’s business records, and receiving Party does not have a duty to maintain its confidentiality; (ii) is publicly available other than as a result of any breach of this Agreement by the receiving Party (from and after the date that such information becomes publicly known); (iii) is subsequently rightfully disclosed to the receiving Party on a non-confidential basis by a Third Party who does not have a duty to preserve its confidentiality; or (iv) is independently discovered or developed by the receiving Party without the use of Confidential Information provided by the disclosing Party, as documented by the receiving Party’s records.

 

6.2                               Return of Confidential Information.  Upon the request of the other Party or within thirty (30) days after any expiration or termination of this Agreement, each Party shall destroy (and certify to the other Party such destruction) or return (as requested by the other Party) all Confidential Information provided by the other Party except as otherwise set forth in this Agreement, and except that each Party may retain a single copy of the Confidential Information in its confidential legal files for the sole purpose of ascertaining its ongoing rights and responsibilities regarding the Confidential Information.

 

6.3                               Permitted Disclosure.  Each Party may disclose Confidential Information provided by the other Party to the extent such disclosure is reasonably necessary in the following instances:

 

(a)         disclosure to governmental or other regulatory agencies in order to obtain patents, or to gain or maintain approval to conduct clinical trials, validation studies or to market Products (in each case to the extent permitted by this Agreement), but such disclosure may be only to the extent reasonably necessary to obtain patents or authorizations;

 

(b)         complying with applicable court orders or governmental regulations, including without limitation rules or regulations of the Securities and Exchange Commission, or by rules of the National Association of Securities Dealers, any securities exchange or NASDAQ; provided, however, that the receiving Party shall

 

8

 

CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED BASED UPON A REQUEST FOR CONFIDENTIAL TREATMENT AND THE NON-PUBLIC INFORMATION HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

first have given notice to the other Party hereto in order to allow such Party the opportunity to seek confidential treatment of the Confidential Information; and

 

(c)          disclosure to consultants, agents or other Third Parties solely to the extent required to accomplish the purposes of this Agreement or in connection with due diligence or similar investigations by such Third Parties, and disclosure to potential Third Party investors in confidential financing documents for the purposes of such financing, in each case on the condition that such Third Parties are bound by confidentiality and non-use obligations at least equivalent in scope to those contained in this Agreement and subject to the protection of privilege with respect to the Common Interest Materials (as defined below).

 

6.4                               Written Agreements.  Each Party shall have in effect or obtain written agreements from each of its employees, consultants and contractors who have access to Confidential Information, which agreements shall obligate such persons to obligations of confidentiality and non-use at least as protective of the Confidential Information of the other Party as the provisions set forth herein.  Each Party will notify the other Party promptly upon discovery of any unauthorized use or disclosure of the Confidential Information of the other Party.

 

6.5                               Joint and Common Interest. To facilitate their performance in connection with this Agreement (including without limitation the preparation, prosecution (including any interferences, reissue proceedings and reexaminations) and maintenance of the Transferred Patents), the parties may share certain information that is protected by the attorney-client privilege, the attorney work product doctrine, and/or other applicable privileges and immunities, including (but not limited to) information regarding their respective analyses of patents and the potential exploitation thereof (collectively, the “Common Interest Materials”).  The parties acknowledge and agree that they have a joint and common legal and commercial interest in sharing the Common Interest Materials in connection with this Agreement.  In furtherance of this Agreement, the parties agree that such sharing and exchange of Common Interest Materials will be subject to the attorney-client privilege, the work product privilege, legal advice privilege and the so-called “Common Interest Doctrine” to the maximum extent possible.  This Agreement memorializes the understanding of the parties that their exchange of the Common Interest Materials is not intended to, and is not understood to, void, waive or compromise in any respect any applicable privilege, protection, immunity, or other legal protection applicable to such information prior to this Agreement and prior to the mutual exchange of information contemplated hereby.

 

6.6                               Required Disclosure.  If a Party is required by judicial or administrative process to disclose Confidential Information that is subject to the non-disclosure provisions of Section 6.1, such Party shall promptly provide reasonable advance written notice to the other Party of the disclosure that is being sought in order to provide the other Party an opportunity to challenge or limit the disclosure obligations.  Each Party shall provide reasonable cooperation to the other Party in any such process.  Confidential Information that is disclosed by judicial or administrative process shall remain otherwise subject to the confidentiality and non-use provisions of this Article 6, and the Party disclosing Confidential Information pursuant to law or court order shall take

 

9

 

CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED BASED UPON A REQUEST FOR CONFIDENTIAL TREATMENT AND THE NON-PUBLIC INFORMATION HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

all reasonable steps necessary, including without limitation obtaining an order of confidentiality, to ensure the continued confidential treatment of such Confidential Information.

 

6.7                               Assertion of Common Interest Doctrine.  If any other person or entity requests or demands, by subpoena or otherwise, any document or other communication received by a party or its counsel pursuant to this Agreement, the requested party will (1) promptly notify the other party, and (2) assert all applicable privileges, including (without limitation) the Common Interest Doctrine, unless attorney-client privilege and all other privileges have previously been waived in writing by the other party.  The requested party further agrees to take all steps reasonable and necessary (including, without limitation, making all appropriate objections and motions) to permit the assertion of all applicable rights and privileges with respect to said Common Interest Materials, and shall cooperate fully in any judicial proceeding relating to the disclosure of the Common Interest Materials.

 

10

 

CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED BASED UPON A REQUEST FOR CONFIDENTIAL TREATMENT AND THE NON-PUBLIC INFORMATION HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

Article 7                                          Intellectual Property

 

7.1           Prosecution and Transferred Patent Status.

 

(a)         GenSignia shall be responsible for the preparation, filing, prosecution and maintenance of the Transferred Patents, including all payment obligations in all the countries in the Territory where such Transferred Patents have been granted and to defend such Transferred Patents from Third Party challenges.  Trovagene shall have the right to participate in the preparation, filing, prosecution (including any interferences, reissue proceedings and reexaminations) and maintenance of the Transferred Patents at Trovagene’s expense.  GenSignia shall reasonably cooperate with Trovagene in the preparation, prosecution and maintenance of the Transferred Patents and upon request by Trovagene, GenSignia shall provide Trovagene with an update of the filing, prosecution and maintenance status for each Transferred Patent.  GenSignia shall not take or fail to take any action with respect to the preparation, prosecution and maintenance of the Transferred Patents that may adversely affect Trovagene without Trovagene’s prior written consent, such consent not to be unreasonably withheld.

 

(b)         GenSignia shall not intentionally fail to file or intentionally abandon in any country any of the Transferred Patents without Trovagene first being given a reasonable and timely opportunity to assume full responsibility for the filing and continued prosecution and maintenance of such Transferred Patents.  In the event that GenSignia decides not to file or prosecute, maintain or defend any Transferred Patent in a country, GenSignia shall provide reasonable notice to Trovagene of such decision and such notice shall be at least sixty (60) days prior to any pending lapse or abandonment thereof.  Thereupon, the ownership of such Transferred Patent in that country shall automatically revert to Trovagene.  GenSigna shall cooperate, at Trovagene’s cost, to execute any documents or take any other actions necessary to effect the ownership of such Transferred Patent in Trovagene, and transfer or cause to be transferred to Trovagene the complete prosecution file for such Transferred Patent(s) with respect to such country, including all correspondence and filings with patent granting authorities in such country with respect to such patent(s) and GenSignia shall have no further rights in such Transferred Patent or pursuant to this Agreement with respect to such Transferred Patent.

 

(c)          In the event that Trovagene or GenSignia becomes aware that a Transferred Patent is challenged in any action or proceeding, such Party shall notify the other Party promptly and shall provide the other Party with available evidence of such suspected infringement or challenge, and following such notification, the Parties shall confer.

 

11

 

CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED BASED UPON A REQUEST FOR CONFIDENTIAL TREATMENT AND THE NON-PUBLIC INFORMATION HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

7.2                               Infringement by Third Parties.

 

(a)         Each Party shall promptly notify the other in writing of any suspected or alleged infringement by Third Parties of any Transferred Patent and provide any information available to that Party relating to such suspected or alleged infringement.

 

(b)         GenSignia shall have the first right, but not the obligation, to initiate and prosecute any legal action or defense with respect to any infringement of Transferred Patents by Third Parties relating to the infringement activities outside the Field but not in or affecting the Field, at its own expense and, if necessary, to name Trovagene as a co-party.  GenSignia shall pay all attorneys’ fees and costs associated with such action; provided, however, that Trovagene may separately represent itself in such prosecution or defense by counsel of its own choice (at Trovagene’s own expense), in which case Trovagene shall cooperate fully with GenSignia.

 

(c)          Trovagene shall have the first right, but not the obligation, to initiate and prosecute any legal action or defense with respect to any infringement of Transferred Patents by Third Parties relating to the infringement activities in or affecting the Field, at its own expense and, if necessary, to name GenSignia as a co-party.  Trovagene shall pay all attorneys’ fees and costs associated with such action; provided, however, that GenSignia may separately represent itself in such prosecution or defense by counsel of its own choice (at GenSignia’s own expense), in which case GenSignia shall cooperate fully with Trovagene.

 

(d)         If, within ninety (90) days of receiving the notice provided for in Section 7.2(b), or thirty (30) days before the time limit, if any, set forth in the appropriate laws and regulations for the filing of such actions, whichever comes first, if the Party with the first right to initiate legal action (the “Initiating Party”) fails to take such action, or if the Initiating Party informs the other Party that it elects not to exercise such first right, the other Party (or its designee) thereafter shall have the right either to initiate and prosecute such action, or to control the defense of such declaratory judgment action, and the other Party shall pay all attorneys’ fees and costs associated with such action; provided, however, that the Initiating Party may separately represent itself in such prosecution or defense by counsel of its own choice (at the Initiating Party’s own expense), in which case the Initiating Party shall cooperate fully with the other Party.

 

(e)          For any action to terminate any infringement of Transferred Patents, if either Party is unable to initiate or prosecute such action solely in its own name, the other Party shall join such action voluntarily and shall execute all documents necessary to initiate litigation to prosecute and maintain such action.  In connection with any such action, GenSignia and Trovagene shall cooperate fully and will provide each other with any information or assistance that either reasonably requests.  Each Party shall keep the other informed of developments in any such action or proceeding, including, to the extent permissible by law, the consultation on and approval of any offer related thereto.

 

12

 

CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED BASED UPON A REQUEST FOR CONFIDENTIAL TREATMENT AND THE NON-PUBLIC INFORMATION HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

(f)           Any recovery obtained by either or both GenSignia and Trovagene in connection with or as a result of any action contemplated by this Section 7.2, whether by settlement or otherwise, shall be first applied toward each Party’s costs and expenses incurred in respect of such action.  If the action was solely initiated by one of the Parties, any recovery amount remaining shall be awarded to the Party that initiated such action, provided, however that any such amounts received by GenSignia shall be subject to payment of Royalties pursuant to Section 3.1(b).  If the action was jointly initiated by the Parties, any recovery amount remaining shall be allocated to each of the Parties in proportion to their respective Net Sales, provided, however that any such amounts received by GenSignia shall be subject to payment of Royalties pursuant to Section 3.1(b).

 

(g)          No settlement of any such action or proceeding which restricts the scope, or adversely affects the enforceability, of a Transferred Patent may be entered into by GenSignia without the prior written consent of Trovagene.  No settlement of any such action or proceeding which restricts the scope or adversely affects the enforceability, of a Transferred Patent outside of the Field may be entered into by Trovagene without the prior written consent of GenSignia.

 

Article 8                                               Indemnification

 

8.1                               Indemnification by Trovagene. Trovagene shall indemnify, defend and hold GenSignia and its officers, directors, shareholders, agents and employees harmless against any and all claims, liability, damage, loss, cost or expense, including reasonable attorney’s fees, (collectively, “Losses”) arising or resulting from any Third Party claim made or suit brought against GenSignia or such persons to the extent any such Losses arise out of (i) any breach by Trovagene of any of its representations or warranties in this Agreement; (ii) Trovagene’s gross negligence or willful misconduct; or (iii) the development, manufacture, use, importation, promotion, marketing, commercialization, distribution and/or sale of Product(s) by Trovagene, or its Affiliates, Distributors, or its sublicensees; provided, however, that Trovagene shall not be required to indemnify GenSignia to the extent it is determined that the Losses resulted from the gross negligence or willful misconduct of GenSignia or to the extent GenSignia would be required to indemnify Trovagene under Section 8.2 below.

 

8.2                                   Indemnification by GenSignia. GenSignia shall indemnify, defend and hold Trovagene, its Affiliates and sublicensees, and its and their officers, directors, shareholders, agents and employees harmless against any and all Losses arising or resulting from any Third Party claim made or suit brought against Trovagene, its Affiliates or sublicensees or such other persons to the extent any such Losses arise out of (i) any breach by GenSignia of any of its representations or warranties in this Agreement; (ii) GenSignia’s gross negligence or willful misconduct; (iii) the development, manufacture, use, importation, promotion, marketing, commercialization, distribution and/or sale of Product(s) by GenSignia, or its Affiliates, Distributors or licensees provided, however, that GenSignia shall not be required to indemnify Trovagene to the extent it is determined that the Losses resulted

 

13

 

CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED BASED UPON A REQUEST FOR CONFIDENTIAL TREATMENT AND THE NON-PUBLIC INFORMATION HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

from the gross negligence or willful misconduct of Trovagene or to the extent Trovagene would be required to indemnify GenSignia under Section 8.1.

 

8.3                                   Limitation Of Liability.  Neither Party shall be liable to the other Party for incidental, consequential or special damages, including but not limited to lost profits, whether in contract, tort or otherwise, arising from or relating to any breach of or activities under this Agreement, regardless of any notice of the possibility of such damages.  Nothing in this Section 8.3 is intended to limit or restrict the indemnification rights or obligations of any Party under this Agreement, nor to relieve a Party from its obligations with respect to any special, indirect, incidental, or consequential damages awarded to a Third Party in circumstances in which such Party is obligated to indemnify the other Party hereunder.

 

Article 9                                          Term and Termination

 

9.1                               Term. This Agreement shall commence on the Effective Date and, unless terminated earlier pursuant to Section 9.2, shall be in full force and effect until the expiration of all Valid Patent Claims.

 

9.2                               Termination for Material Breach. If a Party materially breaches this Agreement, the other Party may terminate this Agreement effective sixty (60) days after providing written notice to the breaching Party, if within that time the breaching Party fails to cure its material breach and the non-breaching Party does not withdraw its termination notice.

 

9.3                               Effects of Termination.  If a Party terminates this Agreement under Section 9.2, all terms and provisions shall terminate as of the effective date of termination, except as otherwise expressly provided in Section 9.4.  In addition, in the event this Agreement is terminated by Trovagene for an uncured GenSignia material breach, (a) ownership of all of the Transferred Patents shall automatically revert to Trovagene; (b) GenSigna shall cooperate to execute any documents or take any other actions necessary to effect the ownership of such Transferred Patents in Trovagene; and (c) GenSignia shall pay any amounts due pursuant to Article 3 with respect to activities prior to the date of termination.  All rights and licenses granted to Trovagene hereunder shall survive the expiration or termination of this Agreement for any reason.

 

9.4                               Accrued Rights and Obligations; Survival.  Termination of this Agreement by a Party pursuant to Section 9.2 shall not be a Party’s sole remedy for a material breach of this Agreement, but shall be in addition to any other rights or remedies of a Party under this Agreement or available at law or in equity.  Termination or expiration of this Agreement shall not affect any accrued rights or surviving obligations of the Parties.  The provisions of Articles 6, 8 and 10 and Sections 2.2, 9.3 and 9.4 shall survive the expiration or termination of this Agreement for any reason whatsoever.

 

14

 

CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED BASED UPON A REQUEST FOR CONFIDENTIAL TREATMENT AND THE NON-PUBLIC INFORMATION HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

Article 10                                   Miscellaneous

 

10.1                        Assignment.  GenSignia may not assign or otherwise transfer the Transferred Patents or any of its rights or obligations under this Agreement to any Third Party without the prior express written consent of Trovagene, which consent shall not be unreasonably withheld, provided, however, that Trovagene may without Trovagene’s prior consent assign or otherwise transfer this Agreement and the Transferred Patents to a third party that acquires all or substantially all of the assets of GenSignia to which this Agreement relates (whether by asset sale, merger, change of control, operation of law or otherwise), provided that (a) such third party has financial resources and experience in connection with the sales of diagnostics that are at least comparable to that of GenSignia; (b) such third party expressly agrees in writing to assume the obligations of GenSignia hereunder.  Trovagene may assign or otherwise transfer (by asset sale, merger, change of control, operation of law or otherwise) its rights or obligations hereunder to any Third Party without consent.  In the event either Party transfers its rights hereunder to a third party such Party shall provide prompt written notice to the other Party of such transfer, no later than thirty (30) days after the date thereof. This Agreement shall be binding upon, and inure to the benefit of, the successors and permitted assigns of the Parties. Any purported assignment or other transfer not in compliance with this Section 10.1 will be void.

 

10.2                        Governing Law.  This Agreement shall be governed and construed in accordance with the laws of the State of California, except for any of its choice of law rules that would require the application of the laws of another jurisdiction.

 

10.3                        Payment Disputes/Arbitration.

 

(a)         In the event of any dispute, controversy or claim relating to the calculation or payment of Royalties or Licensee Income under this Agreement (a “Dispute”), the Parties shall first try to resolve such Dispute amicably.  In this regard, either Party may send a notice of Dispute to the other, and each Party shall appoint, within ten (10) business days from receipt of such notice of Dispute, a senior executive officer of such Party, who will to attempt to negotiate a resolution to such Dispute.  If these representatives fail to resolve the matter within thirty (30) days from their appointment, or if a Party fails to appoint a representative within the ten (10) business day period set forth above, such Dispute shall immediately be referred to the Chief Executive Officer (or such other officer as the Chief Executive Officer may designate) of each Party who will meet and discuss as necessary in order to try to resolve the dispute amicably within the next thirty (30) days.  Should the Parties fail to reach a resolution under this Section 10.3 in the allotted time, at the option of either Party exercisable by written notice of such Party’s desire to arbitration, such unresolved Dispute shall be submitted to and determined finally and exclusively by expedited arbitration in accordance with this Section 10.3.

 

(b)         All Disputes subject to resolution pursuant to this Section 10.3 shall be governed exclusively and finally by expedited arbitration with the American Arbitration Association (“AAA”) in such location as mutually agreed and will be initiated and conducted in accordance with the Commercial Arbitration Rules of the AAA, as

 

15

 

CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED BASED UPON A REQUEST FOR CONFIDENTIAL TREATMENT AND THE NON-PUBLIC INFORMATION HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

such rules are in effect on the date such arbitration is initiated by the Parties, except to the extent that such rules are inconsistent with the provisions of this Agreement and further provided that such expedited arbitration shall be concluded within sixty (60) days of the initiation of arbitration.  The arbitration shall be conducted by one arbitrator mutually selected by the Parties with significant experience in the pharmaceutical or biotechnology industry and with respect to the subject matter of the Dispute at issue.  If the Parties are unable to agree on an arbitrator within ten (10) business days, an arbitrator having the foregoing qualifications shall be designated by the AAA.

 

(c)          The Federal Arbitration Act, 9 U.S.C. §§ 1 and 16, and not state law, shall govern whether or not any Dispute that is subject to this Section 10.3 can be arbitrated.  The arbitrator shall allow such discovery as is appropriate to the purposes of arbitration in accomplishing a fair, speedy and cost-effective resolution of the Dispute.  The arbitrator shall reference the Federal Rules of Civil Procedure then in effect in setting the scope and timing of discovery.  The Federal Rules of Evidence shall apply in toto.  The arbitrator may enter a default decision against any Party who fails to participate in the arbitration proceedings.

 

(d)         The only monetary damages the arbitrator shall have the ability to award are compensatory damages.

 

(e)          Any award by the arbitrator shall be accompanied by a written opinion setting forth the findings of fact and conclusions of law relied upon in reaching the decision.  The award rendered by the arbitrator shall be final, binding and nonappealable, and judgment upon such award may be entered by any court of competent jurisdiction.  The Parties agree that the existence, conduct and content of any arbitration shall be kept confidential and no Party shall disclose to any Person any information about such arbitration, except as may be required by law or by any governmental authority or for financial reporting purposes in each Party’s financial statements.

 

(f)           Each Party shall pay the fees of its own attorneys, expenses of witnesses and all other expenses and costs in connection with the presentation of such Party’s case (collectively, “Attorneys’ Fees”).  The remaining costs of the arbitration, including fees of the arbitrator, costs of records or transcripts and administrative fees (collectively, “Arbitration Costs”) shall be borne equally by the Parties.  Notwithstanding the foregoing, the arbitrator may modify the allocation of Arbitration Costs and award Attorneys’ Fees in those cases where fairness dictates a different allocation of Arbitration Costs between the Parties and an award of Attorneys’ Fees to the prevailing Party as determined by the arbitrator.

 

10.4                        Jurisdiction and Venue. In connection with any dispute arising hereunder, each of the Parties hereby consents to the non-exclusive jurisdiction and venue of the U.S. federal courts located within the state of California and of the California state courts.  Each Party hereby irrevocably waives any right that it may have to assert that any such court lacks jurisdiction or that such forum is not convenient.

 

16

 

CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED BASED UPON A REQUEST FOR CONFIDENTIAL TREATMENT AND THE NON-PUBLIC INFORMATION HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

10.5                        Compliance with Laws.  Each Party shall carry out its activities pursuant to this Agreement in compliance with all applicable supranational, national, state, provincial and other local laws, rules, regulations and guidelines.

 

10.6                        Notice.  All notices, payments or other communications required under this Agreement are deemed fully given when written, addressed and sent as follows:

 

	
All notices to GenSignia are mailed or e-mailed to:
    
	
 
    
	
Name:
    	
Gabriele Cerrone
    
	
Address:
    	
18 South Street, Mayfair, London, UK
    
	
E-mail:
    	
Gabriele@gensignialtd.com
    
	
Phone:
    	
 
    
	
 
    
	
With a copy to:
    
	
 
    
	
Name:
    	
Ivor Elrifi
    
	
Address:
    	
Cooley LLP, 1114 Ave of the Americas, New York, NY   10036
    
	
E-mail:
    	
ielrifi@cooley.com
    
	
Phone:
    	
212 479 6840
    
	
 
    	
 
    
	
All notices to Trovagene are mailed or e-mailed to:
    
	
 
    	
 
    
	
Name:
    	
Michael Terry
    
	
Address:
    	
11055 Flintkote Avenue, Suite B
    
	
 
    	
San Diego, CA 92121
    
	
E-mail:
    	
MTerry@trovagene.com
    
	
Phone:
    	
858.952.7641
    
	
 
    	
 
    
	
With a copy to:
    
	
 
    	
 
    
	
Name:
    	
Susan Hendrickson
    
	
Address:
    	
Arnold & Porter, 555 Twelfth Street, Washington, DC 20004
    
	
E-mail:
    	
Susan.Hendrickson@APORTER.com
    
	
Phone:
    	
202 942 6751
    

 

10.7                        Waiver.  The failure on the part of a Party to exercise or enforce any rights conferred upon it hereunder shall not be deemed to be a waiver of any such rights nor operate to bar the exercise or enforcement thereof at any time or times hereafter

 

10.8                        Bankruptcy.  All rights and licenses granted under or pursuant to this Agreement are, and shall be deemed to be, for purposes of Section 365(n) of the Bankruptcy Code and any similar law or regulation in any other country, licenses of rights to “intellectual property” as defined under Section 101(35A) of the Bankruptcy Code.  The Parties agree that all intellectual property rights licensed hereunder are part of the “intellectual property” as defined under Section 101(35A) of the Bankruptcy Code subject to the protections afforded the non-terminating Party under Section 365(n) of the Bankruptcy Code, and any similar law or regulation in any other country.

 

17

 

CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED BASED UPON A REQUEST FOR CONFIDENTIAL TREATMENT AND THE NON-PUBLIC INFORMATION HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

10.9                        Severability.  The provisions of this Agreement are severable.  If any item or provision of this Agreement shall to any extent be invalid or unenforceable, the remainder of this Agreement shall not be affected thereby, and each term and provision of this Agreement shall be valid and shall be enforced to the fullest extent permitted by law.  The Parties will use diligent good faith efforts to revise this Agreement as and to the extent reasonably necessary to effectuate their original intent and purpose under this Agreement.

 

10.10                 Force Majeure.  The performance by either Party of its respective obligations under this Agreement shall be excused during the period of time that such performance is delayed or prevented in whole or in part by acts of God, fire, floods, storms, explosions, epidemics, war, act or threat of terrorist activity, emergency, civil disorder, strikes, lockouts or other labor difficulties or shortages, or the like (each such event, an “Event of Force Majeure”), provided that the Party whose performance is affected by an Event of Force Majeure immediately notifies the other Party of the occurrence of such event and uses and continues to use commercially reasonable efforts to overcome the same and to resume performance hereunder.

 

10.11                 Entire Agreement; Modification.  This Agreement, including any exhibits expressly named and referenced herein, constitutes the entire agreement and understanding of the Parties and supersedes any prior agreements or understandings relating to the subject matter hereof.  Any modification of this Agreement shall be effective only to the extent it is reduced to writing and signed by a duly authorized representative of each Party hereto.

 

10.12                 Headings.  The captions to the several Articles and Sections hereof are not a part of this Agreement, but are merely for convenience to assist in locating and reading the several Articles and Sections hereof.

 

10.13                 Independent Contractors.  It is expressly agreed that GenSignia and Trovagene shall be independent contractors and that the relationship between the two Parties shall not constitute a partnership, joint venture or agency.  Neither GenSignia nor Trovagene shall have the authority to make any statements, representations or commitments of any kind, or to take any action, which shall be binding on the other Party, without the prior written consent of the other Party.

 

10.14                 Cumulative Remedies.  No remedy referred to in this Agreement is intended to be exclusive, but each shall be cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under law.

 

10.15                 Counterparts.  This Agreement may be executed in one or more counterparts, each of which shall be an original and all of which shall constitute together the same document.

 

10.16                 Exhibits. All Exhibits, schedules and other attachments to this Agreement, and amendments thereto, are by this reference incorporated herein and made a part of this Agreement.

 

18

 

CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED BASED UPON A REQUEST FOR CONFIDENTIAL TREATMENT AND THE NON-PUBLIC INFORMATION HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

The persons executing this Agreement represent and warrant that they have the full power and authority to cause their respective entities to enter into this Agreement.

 

IN WITNESS WHEREOF the Parties have executed this Agreement as of the Effective Date by their duly authorized representatives.

 

 

	
TROVAGENE, INC.
    	
 
    	
GENSIGNIA   IP LTD
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
By:
    	
/s/   Michael Terry
    	
 
    	
By:
    	
/s/   Gabriele Cerrone
    
	
 
    	
Name:
    	
Michael   Terry
    	
 
    	
 
    	
Name:
    	
Gabriele   Cerrone
    
	
 
    	
Title:
    	
Executive   Vice President,
    	
 
    	
 
    	
Title:
    	
Chairman
    
	
 
    	
 
    	
Commercial Operations
    	
 
    	
 
    	
 
    

 

19

 

CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED BASED UPON A REQUEST FOR CONFIDENTIAL TREATMENT AND THE NON-PUBLIC INFORMATION HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

EXHIBIT A: Patents

 

	
Appln./Pat. No.
    	
 
    	
Country
    	
 
    	
Title
    	
 
    	
Filing Date
    	
 
    	
Issue Date
    
	
8,486,626
    	
 
    	
US
    	
 
    	
Methods   of detecting cell-free miRNA in urine and blood
    	
 
    	
08-22-2008
    	
 
    	
07-16-2013
    
	
2,195,450
    	
 
    	
EP
    	
 
    	
Methods   of using mirna for detection of in vivo cell death
    	
 
    	
08-22-2008
    	
 
    	
04-03-2013
    
	
2008289447
    	
 
    	
AU
    	
 
    	
Methods   of using mirna for detection of in vivo cell death
    	
 
    	
08-22-2008
    	
 
    	
 
    
	
2696403
    	
 
    	
CA
    	
 
    	
Methods   of using mirna for detection of in vivo cell death
    	
 
    	
08-22-2008
    	
 
    	
 
    
	
200880113585
    	
 
    	
CN
    	
 
    	
Methods   of using miRNA for detection of in vivo cell death
    	
 
    	
08-22-2008
    	
 
    	
 
    
	
2010-521887
    	
 
    	
JP
    	
 
    	
Methods   of using miRNA for detection of in vivo cell death
    	
 
    	
08-22-2008
    	
 
    	
 
    
	
2006/DELNP/2010
    	
 
    	
IN
    	
 
    	
Methods   of using miRNA for detection of in vivo cell death
    	
 
    	
08-22-2008
    	
 
    	
 
    
	
PCT/US2008/009991
    	
 
    	
PCT
    	
 
    	
Methods   of using miRNA for detection of in vivo cell death
    	
 
    	
08-22-2008
    	
 
    	
 
    
	
60/965,871
    	
 
    	
US
    	
 
    	
Methods   of using miRNA for detection of in vivo cell death
    	
 
    	
08-22-2007
    	
 
    	
 
    

 

20

 

CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED BASED UPON A REQUEST FOR CONFIDENTIAL TREATMENT AND THE NON-PUBLIC INFORMATION HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

EXHIBIT B: Form of Assignment

 

ASSIGNMENT

 

Trovagene Inc. with offices at 11055 Flintkote Avenue, San Diego, California, 92121, the undersigned, for good and valuable consideration, the receipt of which is hereby acknowledged, confirm that we have sold and assigned, and do hereby assign, sell and transfer to GenSignia Inc., with offices at 3030 Bunker Hill Street, Suite 218, San Diego, California, 92109, and to its successors, assigns and legal representatives, collectively hereinafter referred to as the ASSIGNEE:  (1) our entire right, title and interest for the United States and in all countries, in and to any and all inventions, discoveries and applications which are disclosed in the United States Application and the International Patent Application entitled:

 

METHODS OF USING miRNA FOR DETECTION OF IN VIVO CELL DEATH

 

filed with the United States Patent and Trademark Office on August 22, 2007, and assigned Serial No. 60/965,871; filed with the United States Patent and Trademark Office on August 22, 2008, and assigned Serial No. 12/229,378, now U.S. Patent No. 8,486,626, issued July 16, 2013; and filed with the United States Patent and Trademark Office Receiving Office on August 22, 2008, and assigned International Application Serial No. PCT/US2008/009991, and wherein 12/229,378 and PCT/US2008/009991 claim priority to, and the benefit of, U.S. Provisional Application No. 60/965,871, filed on August 22, 2007, and including any national/regional phase applications, European Patent Application No. 08795523, now European Patent No. 2,195,450 B1, granted April 3, 2013, Australian Patent Application No. 2008289447, Canadian Patent Application No. 2696403, Chinese Patent Application No. 200880113585.0, Japanese Patent Application No. 2010-521887 and Indian Patent Application No. 2006/DELNP/2010, any renewals, revivals, reissues, reexaminations, extensions, continuations-in-part, continuations and divisions thereof and any substitute applications therefor; (2) the full and complete right to file patent applications in the name of the ASSIGNEE, its designee, or in my name as the ASSIGNEE, or its designee’s election, on the aforesaid inventions, discoveries and applications in all countries of the world; (3) the entire right, title and interest in and to any Letters Patent which may issue thereon in the United States or in any country, and any renewals, revivals, reissues, reexaminations and extensions thereof, and any patents of confirmation, registration and importation of the same; and (4) the entire right, title and interest in all Convention and Treaty Rights of all kinds thereon, including without limitation all rights of priority in any country of the world, in and to the above inventions, discoveries and applications.

 

We hereby authorize and request the competent authorities to grant and to issue any and all such Letters Patent in the United States and throughout the world to the ASSIGNEE of the entire right, title and interest therein, as fully and entirely as the same would have been held and enjoyed by us had this assignment, sale and transfer not been made.

 

We agree, at any time, upon the request of the ASSIGNEE, to execute and to deliver to the ASSIGNEE any additional applications for patents for said inventions and discoveries, or any part or parts thereof, and any applications for patents of confirmation, registration and importation based on any Letters Patent issuing on said inventions, discoveries, or applications and divisions, continuations, continuations-in-part, renewals, revivals, reissues, reexaminations and extensions thereof.

 

We further agree at any time to execute and to deliver upon request of the ASSIGNEE such additional documents, if any, as are necessary or desirable to secure patent protection on said inventions, discoveries and applications throughout all countries of the world, and otherwise to do the necessary to give full effect to and to perfect the rights of the ASSIGNEE under this Assignment, including the execution, delivery and procurement of any and all further documents evidencing this assignment, transfer and sale as may be necessary or desirable; provided that we shall be reimbursed for reasonable expenses that we may incur.

 

We hereby covenant that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment.

 

21

 

CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED BASED UPON A REQUEST FOR CONFIDENTIAL TREATMENT AND THE NON-PUBLIC INFORMATION HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

We further covenant that ASSIGNEE will, upon its request, be provided promptly with all pertinent facts and documents relating to said invention and said Letters Patent and legal equivalents as may be known and accessible to us and will testify as to the same in any interference, litigation or proceeding related thereto and will promptly execute and deliver to ASSIGNEE or its legal representatives any and all papers, instruments or affidavits required to apply for, obtain, maintain, issue and enforce said application, said invention and said Letters Patent and said equivalents thereof which may be necessary or desirable to carry out the purposes thereof provided that we shall be reimbursed for reasonable expenses that we may incur.

 

 

	
Date:
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
Signature of: Authorized Agent of Trovagene, Inc.
    
	
 
    	
 
    	
 
    
	
State of
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
County of
    	
 
    	
 
    

 

On this              day of                                 , 2014, before me, the undersigned notary public, personally appeared                                             , proved to me through satisfactory evidence of identification, which was a                                             , to be the person whose name is signed on this document and who swore or affirmed to me that the contents of this document are truthful and accurate to the best of his/her knowledge and belief.

 

 

	
 
    	
 
    
	
 
    	
Notary Public
    
	
 
    	
 
    
	
 
    	
My commission expires
    

 

22

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}]]